Psychology and Neuroscience Faculty Database
Psychology and Neuroscience
Arts & Sciences
Duke University
 HOME > Arts & Sciences > pn > Faculty    Search Help Login pdf version printable version 

Publications of Richard S. Keefe    :chronological  combined  bibtex listing:

search PubMed.

Journal Articles

  1. Krystal, A; Pizzagalli, D; Smoski, M; Mathew, S; Nurnberger, J; Lisanby, S; Iosifescu, D; Murrough, J; Weiner, R; Calabrese, J; Sanacora, G; Keefe, R; Song, A; Goodman, W; Szabo, S; Whitten, A; Gao, K; Potter, W (2019). 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. Biological Psychiatry, 85(10), S48-S49. [doi]
  2. Harvey, PD; Ruse, S; Davis, V; Solomon, M; Keefe, R (2012). 14:30 COMPUTERIZED FUNCTIONAL CAPACITY ASSESSMENTIN SCHIZOPHRENIA: EVIDENCE FOR CONVERGENT VALIDITY. Schizophrenia Research, 136, S78-S79. [doi]
  3. Lam, M; Keefe, R; Liu, J-J; Lee, J (2017). 700. Genetic Overlaps between Schizophrenia and Cognition in Asia. Biological Psychiatry, 81(10), S284-S284. [doi]
  4. Keefe, R; Woods, S; Cannon, T; Ruhrmann, S; Mathalon, D; McGuire, P; Fillon, G; Rosenbrock, H; Sand, M (2017). 868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Biological Psychiatry, 81(10), S351-S351. [doi]
  5. Lee, T-S; Goh, SJA; Quek, SY; Phillips, R; Guan, C; Cheung, YB; Feng, L; Teng, SSW; Wang, CC; Chin, ZY; Zhang, H; Ng, TP; Lee, J; Keefe, R; Krishnan, KRR (2013). A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy.. Plos One, 8(11), e79419. [doi]  [abs]
  6. Bratti, I; Marder, SR; Keefe, RS; Bilder, RM (2007). A brief cognitive assessment tool for schizophrenia (B-CATS): Scale construction. Schizophrenia Bulletin, 33(2), 584-584.
  7. Hurford, IM; Marder, SR; Keefe, RSE; Reise, SP; Bilder, RM (2011). A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.. Schizophrenia Bulletin, 37(3), 538-545. [doi]  [abs]
  8. Need, AC; Ge, D; Weale, ME; Maia, J; Feng, S; Heinzen, EL; Shianna, KV; Yoon, W; Kasperaviciūte, D; Gennarelli, M; Strittmatter, WJ; Bonvicini, C; Rossi, G; Jayathilake, K; Cola, PA; McEvoy, JP; Keefe, RSE; Fisher, EMC; St Jean, PL; Giegling, I; Hartmann, AM; Möller, H-J; Ruppert, A; Fraser, G; Crombie, C; Middleton, LT; St Clair, D; Roses, AD; Muglia, P; Francks, C; Rujescu, D; Meltzer, HY; Goldstein, DB (2009). A genome-wide investigation of SNPs and CNVs in schizophrenia.. Plos Genet, 5(2), e1000373. [19197363], [doi]  [abs]
  9. Keefe, RSE; Perkins, DO; Gu, H; Zipursky, RB; Christensen, BK; Lieberman, JA (2006). A longitudinal study of neurocognitive function in individuals at-risk for psychosis.. Schizophrenia Research, 88(1-3), 26-35. [16930949], [doi]  [abs]
  10. Keefe, R (2011). A MODEL OF COGNITIVE OUTCOME MEASURE CHOICE IN EARLY TO LATE PHASE SCHIZOPHRENIA TRIALS. Schizophrenia Bulletin, 37, 309-309.
  11. Kantrowitz, JT; Sharif, Z; Medalia, A; Keefe, RSE; Harvey, P; Bruder, G; Barch, DM; Choo, T; Lee, S; Lieberman, JA (2016). A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.. The Journal of Clinical Psychiatry, 77(6), 799-806. [doi]  [abs]
  12. Chaturvedi, R; Kraus, M; Keefe, RSE (2020). A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia.. Schizophrenia Research, 222, 450-454. [doi]  [abs]
  13. Kollins, SH; DeLoss, DJ; Cañadas, E; Lutz, J; Findling, RL; Keefe, RSE; Epstein, JN; Cutler, AJ; Faraone, SV (2020). A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial.. The Lancet Digital Health, 2(4), e168-e178. [doi]  [abs]
  14. Breier, A; Keefe, RS; Young, CA; Purdon, SE; Gold, JM; Davis, KL (2003). A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia. Schizophrenia Research, 60(1), 274-275. [doi]
  15. Keefe, RS; Roitman, SE; Harvey, PD; Blum, CS; DuPre, RL; Prieto, DM; Davidson, M; Davis, KL (1995). A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.. Schizophrenia Research, 17(1), 25-33. [doi]  [abs]
  16. Jarskog, LF; Lowy, MT; Grove, RA; Keefe, RSE; Horrigan, JP; Ball, MP; Breier, A; Buchanan, RW; Carter, CS; Csernansky, JG; Goff, DC; Green, MF; Kantrowitz, JT; Keshavan, MS; Laurelle, M; Lieberman, JA; Marder, SR; Maruff, P; McMahon, RP; Seidman, LJ; Peykamian, MA (2015). A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.. Schizophrenia Research, 164(1-3), 136-142. [doi]  [abs]
  17. Buchanan, RW; Keefe, RSE; Lieberman, JA; Barch, DM; Csernansky, JG; Goff, DC; Gold, JM; Green, MF; Jarskog, LF; Javitt, DC; Kimhy, D; Kraus, MS; McEvoy, JP; Mesholam-Gately, RI; Seidman, LJ; Ball, MP; McMahon, RP; Kern, RS; Robinson, J; Marder, SR (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.. Biol Psychiatry, 69(5), 442-449. [doi]  [abs]
  18. Weiser, M; Gershon, AA; Rubinstein, K; Petcu, C; Ladea, M; Sima, D; Podea, D; Keefe, RSE; Davis, JM (2012). A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.. Schizophrenia Research, 138(1), 35-38. [doi]  [abs]
  19. Keefe, RSE; Woods, SW; Cannon, TD; Ruhrmann, S; Mathalon, DH; McGuire, P; Rosenbrock, H; Daniels, K; Cotton, D; Roy, D; Pollentier, S; Sand, M (2021). A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale.. Early Interv Psychiatry, 15(5), 1315-1325. [doi]  [abs]
  20. Krystal, AD; Pizzagalli, DA; Smoski, M; Mathew, SJ; Nurnberger, J; Lisanby, SH; Iosifescu, D; Murrough, JW; Yang, H; Weiner, RD; Calabrese, JR; Sanacora, G; Hermes, G; Keefe, RSE; Song, A; Goodman, W; Szabo, ST; Whitton, AE; Gao, K; Potter, WZ (2020). A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.. Nat Med, 26(5), 760-768. [doi]  [abs]
  21. Keefe, R; Canadas, E; Song, D; Farlow, D (2019). A Randomized, Double-Blind, Controlled, 6-Week Trial to Assess a Novel Digital Intervention Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder. Neuropsychopharmacology, 44(SUPPL 1), 425-425.
  22. Buller, R; Mittoux, A; Green, MF; Keefe, R; Forray, C; Schooler, N; Marder, S (2011). A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY EXPLORING THE NEUROCOGNITIVE EFFECT OF SERTINDOLE VS. QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA USING THE MATRICS CONSENSUS COGNITIVE BATTERY (MCCB). Schizophrenia Bulletin, 37, 298-298.
  23. Umbricht, D; Keefe, RSE; Murray, S; Lowe, DA; Porter, R; Garibaldi, G; Santarelli, L (2014). A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.. Neuropsychopharmacology, 39(7), 1568-1577. [doi]  [abs]
  24. Mahableshwarkar, AR; Zajecka, J; Jacobson, W; Chen, Y; Keefe, RS (2016). A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.. Neuropsychopharmacology, 41(12), 2961. [doi]
  25. Mahableshwarkar, AR; Zajecka, J; Jacobson, W; Chen, Y; Keefe, RSE (2015). A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.. Neuropsychopharmacology, 40(8), 2025-2037. [doi]  [abs]
  26. Silverman, JM; Keefe, RS; Mohs, RC; Davis, KL (1989). A study of the reliability of the family history method in genetic studies of Alzheimer disease.. Alzheimer Disease and Associated Disorders, 3(4), 218-223.  [abs]
  27. Keefe, RSE; Nomikos, G; Zhong, W; Christensen, MC; Jacobson, W (2018). A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.. The International Journal of Neuropsychopharmacology, 21(5), 442-447. [doi]  [abs]
  28. Buchanan, RW; Davis, M; Goff, D; Green, MF; Keefe, RSE; Leon, AC; Nuechterlein, KH; Laughren, T; Levin, R; Stover, E; Fenton, W; Marder, SR (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.. Schizophrenia Bulletin, 31(1), 5-19. [doi]  [abs]
  29. Harvey, PD; Keefe, RSE; Patterson, TL; Heaton, RK; Bowie, CR (2009). Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.. J Clin Exp Neuropsychol, 31(4), 462-471. [doi]  [abs]
  30. Kelly, DL; Sullivan, KM; Wehring, HJ; McEvoy, JP; Keefe, R; McMahon, RP; Gold, JM; Feldman, S; Warfel, C; Kearns, AM; Osing, J; Russ, J; Vyas, G; Richardson, CM; August, S; Buchanan, RW (2014). ADJUNCTIVE MINOCYCLINE IN CLOZAPINE TREATED SCHIZOPHRENIA PATIENTS. Schizophrenia Research, 153, S79-S79. [doi]
  31. Sullivan, KM; McEvoy, J; McMahon, RP; Liu, F; Wehring, HJ; Vyas, G; Richardson, CM; Gale, E; Feldman, SM; Russ, JC; Keefe, R; Buchanan, RW; Kelly, DL (2015). ADJUNCTIVE MINOCYCLINE IN CLOZAPINE TREATED SCHIZOPHRENIA PATIENTS: IMPROVEMENTS IN GENERAL HEALTH AND WELL-BEING. Schizophrenia Bulletin, 41, S335-S335.
  32. Kelly, DL; Sullivan, KM; McEvoy, JP; McMahon, RP; Wehring, HJ; Gold, JM; Liu, F; Warfel, D; Vyas, G; Richardson, CM; Fischer, BA; Keller, WR; Koola, MM; Feldman, SM; Russ, JC; Keefe, RSE; Osing, J; Hubzin, L; August, S; Walker, TM; Buchanan, RW (2015). Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.. J Clin Psychopharmacol, 35(4), 374-381. [doi]  [abs]
  33. Frecska, E; Losonczy, MF; Keefe, RSE; Apter, S; Davidson, M; Mohs, RC; Davis, KL (1994). Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis. Biological Psychiatry, 35(9), 704-705. [doi]
  34. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2009). AKT1 and neurocognition in schizophrenia (vol 41, pg 169, 2007). The Australian and New Zealand Journal of Psychiatry, 43(10), 983-983.
  35. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2007). AKT1 and neurocognition in schizophrenia.. The Australian and New Zealand Journal of Psychiatry, 41(2), 169-177. [doi]  [abs]
  36. Narendran, R; Frankle, WG; Keefe, R; Gil, R; Martinez, D; Slifstein, M; Kegeles, LS; Talbot, PS; Huang, Y; Hwang, D-R; Khenissi, L; Cooper, TB; Laruelle, M; Abi-Dargham, A (2005). Altered prefrontal dopaminergic function in chronic recreational ketamine users.. The American Journal of Psychiatry, 162(12), 2352-2359. [doi]  [abs]
  37. Dandash, O; Fornito, A; Lee, J; Keefe, RSE; Chee, MWL; Adcock, RA; Pantelis, C; Wood, SJ; Harrison, BJ (2014). Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.. Schizophrenia Bulletin, 40(4), 904-913. [doi]  [abs]
  38. Kaneda, Y; Keefe, RSE (2015). An abbreviated version of the brief assessment of cognition in schizophrenia (BACS). The European Journal of Psychiatry, 29(2), 131-134. [doi]  [abs]
  39. Barch, DM; Keefe, RSE (2010). Anticipating DSM-V: opportunities and challenges for cognition and psychosis.. Schizophrenia Bulletin, 36(1), 43-47. [doi]  [abs]
  40. Lieberman, JA; Tollefson, GD; Charles, C; Zipursky, R; Sharma, T; Kahn, RS; Keefe, RSE; Green, AI; Gur, RE; McEvoy, J; Perkins, D; Hamer, RM; Gu, H; Tohen, M; HGDH Study Group, (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis.. Archives of General Psychiatry, 62(4), 361-370. [doi]  [abs]
  41. Feber, L; Peter, N; Schneider-Thoma, J; Siafis, S; Bighelli, I; Hansen, W-P; Prates Baldez, D; Salanti, G; Keefe, RSE; Engel, RR; Leucht, S (2023). Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis.. Systematic Reviews, 12(1), 54. [doi]  [abs]
  42. Rapisarda, A; Lim, TF; Lim, M; Collinson, SL; Kraus, MS; Keefe, RSE (2013). Applicability of the MATRICS Consensus Cognitive Battery in Singapore.. Clin Neuropsychol, 27(3), 455-469. [doi]  [abs]
  43. Pani, L; Keefe, RSE (2019). Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues.. Schizophrenia Research. Cognition, 18, 100155. [doi]
  44. Green, MF; Nuechterlein, KH; Gold, JM; Barch, DM; Cohen, J; Essock, S; Fenton, WS; Frese, F; Goldberg, TE; Heaton, RK; Keefe, RSE; Kern, RS; Kraemer, H; Stover, E; Weinberger, DR; Zalcman, S; Marder, SR (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.. Biological Psychiatry, 56(5), 301-307. [doi]  [abs]
  45. Kane, JM; D'Souza, DC; Patkar, AA; Youakim, JM; Tiller, JM; Yang, R; Keefe, RSE (2010). Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.. The Journal of Clinical Psychiatry, 71(11), 1475-1481. [20816042], [doi]  [abs]
  46. Lindenmayer, J-P; Goldring, A; Borne, S; Khan, A; Keefe, RSE; Insel, BJ; Thanju, A; Ljuri, I; Foreman, B (2020). Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia.. Schizophrenia Research, 223, 166-172. [doi]  [abs]
  47. Atkins, AS; Stroescu, I; Spagnola, NB; Davis, VG; Patterson, TD; Narasimhan, M; Harvey, PD; Keefe, RSE (2015). Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).. The Journal of Prevention of Alzheimer'S Disease, 2(2), 121-127. [doi]  [abs]
  48. Atkins, AS; Khan, A; Ulshen, D; Vaughan, A; Balentin, D; Dickerson, H; Liharska, LE; Plassman, B; Welsh-Bohmer, K; Keefe, RSE (2018). Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).. J Prev Alzheimers Dis, 5(4), 216-234. [doi]  [abs]
  49. Roitman, SE; Keefe, RS; Harvey, PD; Siever, LJ; Mohs, RC (1997). Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia.. Schizophrenia Research, 26(2-3), 139-146. [doi]  [abs]
  50. Roitman, SE; Cornblatt, BA; Bergman, A; Obuchowski, M; Mitropoulou, V; Keefe, RS; Silverman, JM; Siever, LJ (1997). Attentional functioning in schizotypal personality disorder.. The American Journal of Psychiatry, 154(5), 655-660. [doi]  [abs]
  51. Harvey, PD; Keefe, RS; Moskowitz, J; Putnam, KM; Mohs, RC; Davis, KL (1990). Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals.. Psychiatry Research, 33(2), 179-188. [doi]  [abs]
  52. Rosenheck, R; Leslie, D; Keefe, R; McEvoy, J; Swartz, M; Perkins, D; Stroup, S; Hsiao, JK; Lieberman, J; CATIE Study Investigators Group, (2006). Barriers to employment for people with schizophrenia.. The American Journal of Psychiatry, 163(3), 411-417. [doi]  [abs]
  53. Keefe, RSE; Bilder, RM; Harvey, PD; Davis, SM; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Miller, DD; Canive, JM; Adler, LW; Manschreck, TC; Swartz, M; Rosenheck, R; Perkins, DO; Walker, TM; Stroup, TS; McEvoy, JP; Lieberman, JA (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial.. Neuropsychopharmacology, 31(9), 2033-2046. [16641947], [doi]  [abs]
  54. Chakos, MH; Glick, ID; Miller, AL; Hamner, MB; Miller, DD; Patel, JK; Tapp, A; Keefe, RSE; Rosenheck, RA (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.. Psychiatric Services (Washington, D.C.), 57(8), 1094-1101. [doi]  [abs]
  55. Kraus, MS; Walker, TM; Perkins, D; Keefe, RSE (2022). Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis.. Schizophrenia Research. Cognition, 27, 100225. [doi]
  56. Kraus, MS; Walker, TM; Jarskog, LF; Millet, RA; Keefe, RSE (2019). Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia.. Schizophrenia Research, 204, 155-161. [doi]  [abs]
  57. Ethridge, LE; Soilleux, M; Nakonezny, PA; Reilly, JL; Hill, SK; Keefe, RSE; Gershon, ES; Pearlson, GD; Tamminga, CA; Keshavan, MS; Sweeney, JA (2014). Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.. Schizophrenia Research, 159(2-3), 491-498. [doi]  [abs]
  58. Horan, B; Hake, S; Huang, S; Zhao, Y; Keefe, R; Atkins, A; Podhorna, J (2020). BI 425809 Once Daily in Patients With Schizophrenia: Feasibility of Novel Endpoints to Assess Motivation. Neuropsychopharmacology, 45(SUPPL 1), 131-132.
  59. Reise, SP; Ventura, J; Keefe, RSE; Baade, LE; Gold, JM; Green, MF; Kern, RS; Mesholam-Gately, R; Nuechterlein, KH; Seidman, LJ; Bilder, R (2011). Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.. Psychol Assess, 23(1), 245-261. [doi]  [abs]
  60. Geffen, Y; Keefe, R; Rabinowitz, J; Anand, R; Davidson, M (2012). Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.. The Journal of Clinical Psychiatry, 73(9), e1168-e1174. [doi]  [abs]
  61. Eng, GK; Lam, M; Bong, YL; Subramaniam, M; Bautista, D; Rapisarda, A; Kraus, M; Lee, J; Collinson, SL; Chong, SA; Keefe, RSE (2013). Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample.. Arch Clin Neuropsychol, 28(8), 845-858. [Gateway.cgi], [doi]  [abs]
  62. Kaneda, Y; Sumiyoshi, T; Keefe, R; Ishimoto, Y; Numata, S; Ohmori, T (2007). Brief assessment of cognition in schizophrenia: validation of the Japanese version.. Psychiatry and Clinical Neurosciences, 61(6), 602-609. [doi]  [abs]
  63. Harvey, PD; Putnam, KM; Davidson, M; Kahn, RS; Powchik, P; McQueeney, R; Keefe, RS; Davis, KL (1991). Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.. Psychiatry Research, 38(3), 285-292. [doi]  [abs]
  64. Seccomandi, B; Agbedjro, D; Bell, M; Keefe, RSE; Keshavan, M; Galderisi, S; Fiszdon, J; Mucci, A; Cavallaro, R; Bechi, M; Ojeda, N; Peña, J; Wykes, T; Cella, M (2021). Can IQ moderate the response to cognitive remediation in people with schizophrenia?. J Psychiatr Res, 133, 38-45. [doi]  [abs]
  65. Sethuraman, G; Ahmed, S; Rock, SL; Young, CA; Marquez, EM; Purdon, SE; Keefe, RS (2004). Can the panss cognitive factor be a valid surrogate for neurocognition in schizophrenia?. The International Journal of Neuropsychopharmacology, 7, S226-S226.
  66. KEEFE, RSE; MOHS, RC; SILVERMAN, JM; LOSONCZY, MF; DAVIDSON, M; HORVATH, TB; DAVIS, KL (1990). CHARACTERISTICS OF KRAEPELINIAN SCHIZOPHRENIA AND THEIR RELATION TO PREMORBID SOCIOSEXUAL FUNCTIONING. NEUROLEPTIC-NONRESPONSIVE PATIENT : CHARACTERIZATION AND TREATMENT, 27, 1-+.
  67. Keefe, RSE; Fox, KH; Harvey, PD; Cucchiaro, J; Siu, C; Loebel, A (2011). Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.. Schizophrenia Research, 125(2-3), 161-168. [doi]  [abs]
  68. Keefe, RS; Mohs, RC; Losonczy, MF; Davidson, M; Silverman, JM; Kendler, KS; Horvath, TB; Nora, R; Davis, KL (1987). Characteristics of very poor outcome schizophrenia.. The American Journal of Psychiatry, 144(7), 889-895. [doi]  [abs]
  69. Hufford, MR; Davis, VG; Hilt, D; Dgetluck, N; Geffen, Y; Loebel, A; Haig, G; Santarelli, L; Keefe, RSE (2014). Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.. Schizophrenia Research, 159(1), 205-210. [doi]  [abs]
  70. Goldberg, TE; Keefe, RSE; Goldman, RS; Robinson, DG; Harvey, PD (2010). Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.. Neuropsychopharmacology, 35(5), 1053-1062. [doi]  [abs]
  71. Keefe, RS; Frescka, E; Apter, SH; Davidson, M; Macaluso, JM; Hirschowitz, J; Davis, KL (1996). Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings.. The American Journal of Psychiatry, 153(6), 806-811. [doi]  [abs]
  72. Miller, DD; McEvoy, JP; Davis, SM; Caroff, SN; Saltz, BL; Chakos, MH; Swartz, MS; Keefe, RSE; Rosenheck, RA; Stroup, TS; Lieberman, JA (2005). Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.. Schizophrenia Research, 80(1), 33-43. [16171976], [doi]  [abs]
  73. Keefe, RSE; Buchanan, RW; Marder, SR; Schooler, NR; Dugar, A; Zivkov, M; Stewart, M (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?. Schizophrenia Bulletin, 39(2), 417-435. [Gateway.cgi], [doi]  [abs]
  74. Keefe, RSE; Kraus, MS (2012). Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.. American Journal of Psychiatry, 169(4), 354-357. [doi]
  75. Kern, RS; Green, MF; Nuechterlein, KH; Keefe, RSE (2009). CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.. Schizophrenia Research, 107(2-3), 327-329. [doi]
  76. Keefe, RSE (2014). Cognition and motivation as treatment targets in schizophrenia.. Jama Psychiatry, 71(9), 987-988. [doi]
  77. Lam, M; Lee, J; Keefe, R; Teo, YY (2015). COGNITION AND PSYCHOMETRIC SUPPRESSOR EFFECTS OF SCN2A IN SCHIZOPHRENIA. Schizophrenia Bulletin, 41, S52-S52.
  78. Targum, SD; Keefe, RSE (2008). Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?. Psychiatry (Edgmont (Pa. : Township)), 5(12), 55-59.
  79. Keefe, RSE (2004). Cognition and the concept of schizotaxia. European Psychiatry, 19, 114S-114S.
  80. Keefe, RSE (2004). Cognition as a key to alliance, adherence, and functional outcomes. The International Journal of Neuropsychopharmacology, 7, S106-S106.
  81. Kraus, MS; Keefe, RSE (2007). Cognition as an outcome measure in schizophrenia.. The British Journal of Psychiatry. Supplement, 50(SUPPL. 50), s46-s51. [doi]  [abs]
  82. Nutt, D; Gispen-de Wied, CC; Arango, C; Keefe, RSE; Penadés, R; Murphy, DG; Robbins, TW; Sahakian, BJ (2013). Cognition in schizophrenia: summary Nice Consultation Meeting 2012.. Eur Neuropsychopharmacol, 23(8), 769-778. [doi]
  83. Volovyk, S; Keefe, R; Loganovsky, K; Bazyka, D (2010). Cognitive and behavioral dysfunction under ionizing radiation exposure. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology, 77(3), 341-341. [doi]
  84. Segarra, N; Bernardo, M; Justicia, A; Fernadez-Egea, E; Gutierrez, F; Allas, M; Contreras, F; Safont, G; Gascon, J; Menchon, J; Keefe, R (2009). COGNITIVE ASSESSMENT IN PATIENTS WITH FIRST EPISODE PSYCHOSIS USING SPANISH BACS (BRIEF ASSESSMENT IN COGNITION IN SCHIZOPHRENIA). Schizophrenia Bulletin, 35, 286-287.
  85. Eum, S; Hill, SK; Rubin, LH; Carnahan, RM; Reilly, JL; Ivleva, EI; Keedy, SK; Tamminga, CA; Pearlson, GD; Clementz, BA; Gershon, ES; Keshavan, MS; Keefe, RSE; Sweeney, JA; Bishop, JR (2017). Cognitive burden of anticholinergic medications in psychotic disorders.. Schizophrenia Research, 190, 129-135. [doi]  [abs]
  86. Keefe, RSE; Kahn, RS (2017). Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia.. Jama Psychiatry, 74(5), 535-536. [doi]
  87. Keefe, RSE (2007). Cognitive deficits in patients with schizophrenia: effects and treatment.. The Journal of Clinical Psychiatry, 68 Suppl 14(SUPPL. 14), 8-13.  [abs]
  88. Kern, RS; Gold, JM; Dickinson, D; Green, MF; Nuechterlein, KH; Keefe, RSE; Marder, SR; Sugar, CA (2010). COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS). Schizophrenia Research, 117(2-3), 323-324. [doi]
  89. Davidson, M; Galderisi, S; Weiser, M; Werbeloff, N; Fleischhacker, WW; Keefe, RS; Boter, H; Keet, IPM; Prelipceanu, D; Rybakowski, JK; Libiger, J; Hummer, M; Dollfus, S; López-Ibor, JJ; Hranov, LG; Gaebel, W; Peuskens, J; Lindefors, N; Riecher-Rössler, A; Kahn, RS (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).. American Journal of Psychiatry, 166(6), 675-682. [doi]  [abs]
  90. Vigen, CLP; Mack, WJ; Keefe, RSE; Sano, M; Sultzer, DL; Stroup, TS; Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Tariot, PN; Zheng, L; Schneider, LS (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.. American Journal of Psychiatry, 168(8), 831-839. [doi]  [abs]
  91. Schneider, LS; Vigen, CL; Mack, WJ; Dagerman, KS; Keefe, R; Sano, M; Sultzer, D; Stroup, S; Hsiao, J; Lebowitz, B; Lyketsos, CG; Tariot, PN; Zheng, L (2009). Cognitive Effects of Atypical Antipsychotics in Patients with Alzheimer's Disease: Outcomes from CATIE-AD. American Journal of Geriatric Psychiatry, 17(3), A76-A76.
  92. Keefe, RSE; Harvey, PD; Khan, A; Saoud, JB; Staner, C; Davidson, M; Luthringer, R (2018). Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.. The Journal of Clinical Psychiatry, 79(3). [doi]  [abs]
  93. Keefe, RSE; McClintock, SM; Roth, RM; Doraiswamy, PM; Tiger, S; Madhoo, M (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.. The Journal of Clinical Psychiatry, 75(8), 864-876. [doi]  [abs]
  94. Sharma, T; Harvey, PD; Kumari, V; Keefe, RSE (2004). Cognitive enhancement in schizophrenia: Ending the therapeutic nihilism. Biological Psychiatry, 55, 151S-151S.
  95. Trestman, RL; Keefe, RS; Mitropoulou, V; Harvey, PD; deVegvar, ML; Lees-Roitman, S; Davidson, M; Aronson, A; Silverman, J; Siever, LJ (1995). Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder.. Psychiatry Research, 59(1-2), 127-136. [Gateway.cgi], [doi]  [abs]
  96. Schooler, N; Khan, A; Keefe, R; Marcy, P; Robinson, D; Kane, J (2016). Cognitive Functioning in First Episode Psychosis: Comparison of a Two-Year Coordinated Specialty Care Program to Community Care. Neuropsychopharmacology, 41, S593-S593.
  97. Schooler, N; Khan, A; Keefe, R; Robinson, D; Kane, J (2017). COGNITIVE FUNCTIONING IN FIRST-EPISODE PSYCHOSIS:_X000B_COMPARISON OF A 2-YEAR COORDINATED SPECIALTY CARE PROGRAM TO COMMUNITY CARE. Schizophrenia Bulletin, 43, S24-S24.
  98. Harvey, PD; Green, MF; Keefe, RSE; Velligan, DI (2004). Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.. The Journal of Clinical Psychiatry, 65(3), 361-372. [doi]  [abs]
  99. Davidson, M; Keefe, RS (1995). Cognitive impairment as a target for pharmacological treatment in schizophrenia.. Schizophrenia Research, 17(1), 123-129. [doi]
  100. Fox, KH; Burdick, KE; Lombardo, I; Keefe, RSE (2009). Cognitive impairment in patients with bipolar disorder. Psychiatric Times, 26(12), 66-68.
  101. Harvey, PD; Keefe, RSE (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. Cns Spectrums, 2(8), 41-55. [doi]  [abs]
  102. Keefe, RSE; Harvey, PD (2012). Cognitive impairment in schizophrenia.. Handbook of Experimental Pharmacology, 213(213), 11-37. [doi]  [abs]
  103. McCutcheon, RA; Keefe, RSE; McGuire, PK (2023). Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.. Mol Psychiatry, 28(5), 1902-1918. [doi]  [abs]
  104. Nasrallah, HA; Keefe, RSE; Davis, S; Mcevoy, J; Goff, D; Meyer, J; Stroup, TS; Lieberman, JA (2007). Cognitive improvement correlates with weight gain in schizophrenia subjects receiving quetiapine but not other antipsychotics: Data from the CATIE trial. Biological Psychiatry, 61(8), 247S-248S.
  105. Sweeney, J; Keefe, R; Hill, S (2011). COGNITIVE PHENOTYPES FOR SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR DISORDER IN THE BSNIP STUDY. Schizophrenia Bulletin, 37, 230-230.
  106. Lipkovich, I; Kollack-Walker, S; Kinon, BJ; Stauffer, V; Ascher-Svanum, H; Keefe, R (2007). Cognitive status of patients with schizophrenia as modulator or mediator of functional outcome. Biological Psychiatry, 61(8), 246S-246S.
  107. Lim, K; Smucny, J; Barch, DM; Lam, M; Keefe, RSE; Lee, J (2021). Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis.. Schizophrenia Bulletin, 47(3), 712-721. [doi]  [abs]
  108. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Lewine, RRJ; Yurgelun-Todd, DA; Gur, RC; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA (2009). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol (American Journal of Psychiatry (2004) 161, (985-995)). The American Journal of Psychiatry, 166(8), 942.
  109. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Lewine, RRJ; Yurgelun-Todd, DA; Gur, RC; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.. The American Journal of Psychiatry, 161(6), 985-995. [15169686], [doi]  [abs]
  110. Lieberman, J; Stroup, S; Fleischhacker, WW; Lewis, S; Swartz, M; Keefe, R; Essock, S (2006). Comparative effectiveness of antipsychotic drugs: Complete results of the CATIE study. Neuropsychopharmacology, 31, S12-S12.
  111. Kraus, M; Walker, T; Jarskog, L; Jones, K; Millet, R; Keefe, R (2016). Comprehensive Assessment of Auditory Perception and its Relation to Impaired Emotion Recognition in Schizophrenia. Neuropsychopharmacology, 41, S251-S252.
  112. Krishnan, RR; Kraus, MS; Keefe, RSE (2011). Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?. Psychiatry and Clinical Neurosciences, 65(4), 305-317. [doi]  [abs]
  113. Harvey, PD; Khan, A; Atkins, A; Walker, TM; Keefe, RSE (2019). Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS).. Schizophrenia Research, 210, 30-38. [doi]  [abs]
  114. Horan, B; Depp, C; Hurst, S; Klein, H; Harvey, P; Keefe, R (2022). Content Validation of a Functional Co-Primary Measure for Clinical Trials Targeting Cognitive Impairment Associated With Schizophrenia (CIAS): An FDA-Funded Study. Neuropsychopharmacology, 47, 383-384.
  115. McCutcheon, RA; Keefe, RSE; McGuire, PK (2023). Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.. Mol Psychiatry, 28(5), 1919. [doi]
  116. Chan, W-Y; Yang, G-L; Chia, M-Y; Woon, P-S; Lee, J; Keefe, R; Sitoh, Y-Y; Nowinski, WL; Sim, K (2010). Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics.. Bipolar Disord, 12(4), 383-389. [doi]  [abs]
  117. Ho, NF; Lee, BJH; Tng, JXJ; Lam, MZY; Chen, G; Wang, M; Zhou, J; Keefe, RSE; Sim, K (2020). Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study.. Eur Psychiatry, 63(1), e40. [doi]  [abs]
  118. Rosenheck, RA; Leslie, DL; Sindelar, J; Miller, EA; Lin, H; Stroup, TS; McEvoy, J; Davis, SM; Keefe, RSE; Swartz, M; Perkins, DO; Hsiao, JK; Lieberman, J; CATIE Study Investigators, (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.. The American Journal of Psychiatry, 163(12), 2080-2089. [doi]  [abs]
  119. Greenberg, G; Rosenheck, RA; Erickson, SK; Desai, RA; Stefanovics, EA; Swartz, M; Keefe, RSE; McEvoy, J; Stroup, TS; CATIE Investigators, (2011). Criminal justice system involvement among people with schizophrenia.. Community Mental Health Journal, 47(6), 727-736. [doi]  [abs]
  120. Siegel, BV; Trestman, RL; O'Flaithbheartaigh, S; Mitropoulou, V; Amin, F; Kirrane, R; Silverman, J; Schmeidler, J; Keefe, RS; Siever, LJ (1996). D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder.. Schizophrenia Research, 20(1-2), 29-32. [doi]  [abs]
  121. Stroup, S; Appelbaum, P; Swartz, M; Patel, M; Davis, S; Jeste, D; Kim, S; Keefe, R; Manschreck, T; McEvoy, J; Lieberman, J (2005). Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.. Schizophrenia Research, 80(1), 1-8. [doi]  [abs]
  122. Eskridge, CLM; Hochberger, WC; Kaseda, ET; Lencer, R; Reilly, JL; Keedy, SK; Keefe, RSE; Pearlson, GD; Keshavan, MS; Tamminga, CA; Sweeney, JA; Hill, SK (2021). Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders.. Schizophrenia Research, 236, 54-60. [doi]  [abs]
  123. Kraus, M; Keefe, R; Krishnan, R (2011). DEFICITS IN LEARNING-DEPENDENT PREDICTIVE PERCEPTION AND THEIR RELATIONSHIP TO COGNITIVE IMPAIRMENT AND REALITY DISTORTION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 37, 215-215.
  124. Keefe, RSE; Kraemer, HC; Epstein, RS; Frank, E; Haynes, G; Laughren, TP; McNulty, J; Reed, SD; Sanchez, J; Leon, AC (2013). Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.. Innovations in Clinical Neuroscience, 10(5-6 Suppl A), 4S-19S.  [abs]
  125. Keefe, RS; Eesley, CE; Poe, MP (2004). Defining a cognitive function decrement in schizophrenia. Biological Psychiatry, 55, 41S-41S.
  126. Keefe, RSE; Eesley, CE; Poe, MP (2005). Defining a cognitive function decrement in schizophrenia.. Biological Psychiatry, 57(6), 688-691. [doi]  [abs]
  127. Vocisano, C; Klein, DN; Keefe, RS; Dienst, ER; Kincaid, MM (1996). Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder.. The American Journal of Psychiatry, 153(2), 248-255. [doi]  [abs]
  128. Gray, BE; McMahon, RP; Green, MF; Seidman, LJ; Mesholam-Gately, RI; Kern, RS; Nuechterlein, KH; Keefe, RS; Gold, JM (2014). Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.. Schizophrenia Research, 159(1), 182-187. [doi]  [abs]
  129. Brady, L; Eremenc, S; Keefe, R; Trivedi, M; Sand, M; Koblan, K; Stafford, E; Streiff, R; Lisanby, S (2022). Developing Novel Clinical Outcome Assessments (COAs) for Psychiatric Illnesses. Neuropsychopharmacology, 47, 2-3.
  130. Kleinman, L; Lieberman, J; Dube, S; Mohs, R; Zhao, Y; Kinon, B; Carpenter, W; Harvey, PD; Green, MF; Keefe, RSE; Frank, L; Bowman, L; Revicki, DA (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.. Schizophrenia Research, 107(2-3), 275-285. [doi]  [abs]
  131. Atkins, A; Tseng, T; Vaughan, A; Harvey, P; Narasimhan, M; Patterson, T; Khan, A; Keefe, R (2017). DEVELOPMENT AND VALIDATION OF THE BRIEF ASSESSMENT OF VALIDATION IN SCHIZOPHRENIA (BAC-APP). Schizophrenia Bulletin, 43, S220-S220.
  132. Ruse, SA; Davis, VG; Atkins, AS; Krishnan, KRR; Fox, KH; Harvey, PD; Keefe, RSE (2014). Development of a virtual reality assessment of everyday living skills. Journal of Visualized Experiments : Jove, 86. [doi]  [abs]
  133. Ruse, SA; Davis, VG; Atkins, AS; Krishnan, KRR; Fox, KH; Harvey, PD; Keefe, RSE (2014). Development of a virtual reality assessment of everyday living skills.. Journal of Visualized Experiments : Jove, 86. [doi]  [abs]
  134. Ventura, J; Bilder, RM; Reise, SR; Keefe, RS (2009). DEVELOPMENT OF AN INTERVIEW-BASED "CO-PRIMARY'' MEASURE OF COGNITION. Schizophrenia Bulletin, 35, 21-22.
  135. Goldberg, TE; Harvey, PD; Devanand, DP; Keefe, RSE; Gomar, JJ (2020). Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer's Disease Spectrum.. The Journal of Prevention of Alzheimer'S Disease, 7(3), 179-183. [doi]  [abs]
  136. Hochberger, WC; Combs, T; Reilly, JL; Bishop, JR; Keefe, RSE; Clementz, BA; Keshavan, MS; Pearlson, GD; Tamminga, CA; Hill, SK; Sweeney, JA (2018). Deviation from expected cognitive ability across psychotic disorders.. Schizophrenia Research, 192, 300-307. [doi]  [abs]
  137. Keefe, RS; Lobel, DS; Mohs, RC; Silverman, JM; Harvey, PD; Davidson, M; Losonczy, MF; Davis, KL (1991). Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms.. Schizophrenia Research, 4(2), 71-79. [doi]  [abs]
  138. Lamonica, HM; Keefe, RSE; Harvey, PD; Gold, JM; Goldberg, TE (2010). Differential effects of emotional information on interference task performance across the life span.. Frontiers in Aging Neuroscience, 2. [Gateway.cgi], [doi]  [abs]
  139. Keefe, RSE; Cañadas, E; Farlow, D; Etkin, A (2022). Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults.. American Journal of Psychiatry, 179(7), 482-489. [doi]  [abs]
  140. Williamson, DJ; Nuechterlein, KH; Tishler, T; Ventura, J; Ellingson, BM; Turkoz, I; Keefe, RSE; Alphs, L (2022). Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective.. Schizophrenia Research. Cognition, 30, 100270. [doi]  [abs]
  141. Kraus, M; Rapisarda, A; Lam, M; Thong, JYJ; Lee, J; Subramaniam, M; Collinson, SL; Chong, SA; Keefe, RSE (2016). Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis.. Schizophrenia Research. Cognition, 6, 1-8. [doi]  [abs]
  142. Wang, C; Ji, F; Hong, Z; Poh, JS; Krishnan, R; Lee, J; Rekhi, G; Keefe, RSE; Adcock, RA; Wood, SJ; Fornito, A; Pasternak, O; Chee, MWL; Zhou, J (2016). Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study.. Psychol Med, 46(13), 2771-2783. [doi]  [abs]
  143. Keefe, RSE; Bollini, AM; Silva, SG (1999). Do novel antipsychotics improve cognition? A report of a meta-analysis. Psychiatric Annals, 29(11), 623-629. [doi]
  144. Keefe, RSE; Courtney, M; Bayan, UJ; Harvey, PD; McEvoy, JM (1998). Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?. Schizophrenia Research, 29(1-2), 36-36. [doi]
  145. Uchida, H; Sakurai, H; Bies, RR; Stroup, S; Keefe, RSE; Suzuki, T; Tsuboi, T; Mimura, M; Pollock, BG; Mamo, DC (2012). DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA. Schizophrenia Research, 136, S359-S359.
  146. Sakurai, H; Bies, RR; Stroup, ST; Keefe, RSE; Rajji, TK; Suzuki, T; Mamo, DC; Pollock, BG; Watanabe, K; Mimura, M; Uchida, H (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.. Schizophrenia Bulletin, 39(3), 564-574. [doi]  [abs]
  147. Harvey, PD; Kahn, RS; Davidson, M; Mohs, RC; Keefe, RSE; Davis, KL (1992). Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients. Schizophrenia Research, 6(2), 136-136. [doi]
  148. Kantrowitz, JT; Medalia, A; Keefe, RSE; Harvey, PD; Bruder, G; Barch, DM; Choo, T; Lee, S; Lieberman, JA (2016). Dr Kantrowitz and Colleagues Reply.. The Journal of Clinical Psychiatry, 77(10), e1353. [doi]
  149. Keefe, RSE; Sweeney, JA; Gu, H; Hamer, RM; Perkins, DO; McEvoy, JP; Lieberman, JA (2007). Dr. Keefe and colleagues reply. The American Journal of Psychiatry, 164(12), 1911-1912. [doi]
  150. LIEBERMAN, JA; STROUP, TS; McEVOY, JP; SWARTZ, MS; ROSENHECK, RA; PERKINS, DO; KEEFE, RSE; DAVIS, SM; DAVIS, CE; HSIAO, J; SEVERE, J; LEBOWITZ, BD; the CATIE Investigators, (2006). Dr. Lieberman and Colleagues Reply. The American Journal of Psychiatry, 163(3), 555-556. [doi]
  151. Lieberman, JA; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, SM; Davis, CE; Hsiao, J; Severe, J; Lebowitz, BD (2006). Dr. Lieberman and Colleagues reply [17]. The American Journal of Psychiatry, 163(3), 555-556. [doi]
  152. ROSENHECK, R; STROUP, TS; SWARTZ, M; McEVOY, J; DAVIS, SM; KEEFE, RSE; HSIAO, JK; LIEBERMAN, J (2007). Dr. Rosenheck and Colleagues Reply. The American Journal of Psychiatry, 164(4), 678-680. [doi]
  153. Rosenheck, R; Stroup, TS; Swartz, M; McEvoy, J; Davis, SM; Keefe, RSE; Hsiao, JK; Lieberman, J (2007). Dr. Rosenheck and colleagues reply [2]. The American Journal of Psychiatry, 164(4), 678-680. [doi]
  154. Carpenter, W; Hofer, A; Keefe, R; Mueser, K; Naber, D; Chen, E (2010). DSM-V: NEW PARADIGMS AND OTHER CONTROVERSIES. Schizophrenia Research, 117(2-3), 110-110. [doi]
  155. Keefe, R; Woods, S; Cannon, T; Ruhrmann, S; Mathalon, D; McGuire, P; Fillon, G; Rosenbrock, H; Sand, M (2017). EARLY INTERVENTION IN ATTENUATED PSYCHOSIS SYNDROME: A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 409306. Schizophrenia Bulletin, 43, S216-S216.
  156. Keefe, R; Khan, A; Staner, C; Reilly, J; Saoud, J; Davidson, M; Luthringer, R (2016). Effect of MIN-101on Cognition of in Schizophrenia Patient With Predominant Negative Symptoms: A 12-Week Randomized, Double Blind, Placebo-Controlled Trial. Neuropsychopharmacology, 41, S389-S390.
  157. Hawkins, KA; Addington, J; Keefe, RSE; Christensen, BK; Woods, SW; Miller, TJ; Trzaskoma, QN; Breier, A; Zipursky, RB; Perkins, DO; McGlashan, TH (2004). Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Biological Psychiatry, 55, 27S-27S.
  158. Hawkins, KA; Addington, J; Keefe, RS; Christensen, B; Woods, SW; Miller, TJ; Trzaskoma, QN; Breier, A; Zipursky, RB; Perkins, DO (2004). Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects. Schizophrenia Research, 67(1), 205-205.
  159. Javitt, DC; Buchanan, RW; Keefe, RSE; Kern, R; McMahon, RP; Green, MF; Lieberman, J; Goff, DC; Csernansky, JG; McEvoy, JP; Jarskog, F; Seidman, LJ; Gold, JM; Kimhy, D; Nolan, KS; Barch, DS; Ball, MP; Robinson, J; Marder, SR (2012). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.. Schizophrenia Research, 136(1-3), 25-31. [doi]  [abs]
  160. Lieberman, JA; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, SM; Davis, CE; Lebowitz, BD; Severe, J; Hsiao, JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.. The New England Journal of Medicine, 353(12), 1209-1223. [16172203], [doi]  [abs]
  161. Lieberman, JA; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Keefe, RS; Davis, SM; Davis, CE; Lebowitz, B; Hsiao, J; Severe, J (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Neuropsychopharmacology, 30, S32-S32.
  162. McEvoy, JP; Lieberman, JA; Stroup, TS; Davis, SM; Meltzer, HY; Rosenheck, RA; Swartz, MS; Perkins, DO; Keefe, RSE; Davis, CE; Severe, J; Hsiao, JK; CATIE Investigators, (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.. The American Journal of Psychiatry, 163(4), 600-610. [16585434], [doi]  [abs]
  163. Stroup, TS; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Capuano, GA; Rosenheck, RA; Keefe, RSE; Miller, AL; Belz, I; Hsiao, JK; CATIE Investigators, (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.. The American Journal of Psychiatry, 164(3), 415-427. [17329466], [doi]  [abs]
  164. Stroup, TS; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Rosenheck, RA; Perkins, DO; Keefe, RSE; Davis, CE; Severe, J; Hsiao, JK; CATIE Investigators, (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.. The American Journal of Psychiatry, 163(4), 611-622. [16585435], [doi]  [abs]
  165. Tiller, J; D'Souza, DC; Keefe, RSE; Kane, JM; Patkar, AA; Youakim, JM (2009). Effects of Adjunctive Armodafinil on Patients with Schizophrenia. Neurology, 72(11), A336-A336.
  166. Swartz, MS; Perkins, DO; Stroup, TS; Davis, SM; Capuano, G; Rosenheck, RA; Reimherr, F; McGee, MF; Keefe, RSE; McEvoy, JP; Hsiao, JK; Lieberman, JA; CATIE Investigators, (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.. The American Journal of Psychiatry, 164(3), 428-436. [17329467], [doi]  [abs]
  167. Cella, M; Stahl, D; Morris, S; Keefe, R; Bell, MD; Heinssen, R; Wykes, T (2015). EFFECTS OF COGNITIVE REMEDIATION ON NEGATIVE SYMPTOMS DIMENSIONS: EXPLORING THE ROLE OF WORKING MEMORY. Schizophrenia Bulletin, 41, S40-S41.
  168. Cella, M; Stahl, D; Morris, S; Keefe, RSE; Bell, MD; Wykes, T (2017). Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory.. Psychol Med, 47(15), 2593-2601. [doi]  [abs]
  169. Jarskog, LF; Dong, Z; Kangarlu, A; Colibazzi, T; Girgis, RR; Kegeles, LS; Barch, DM; Buchanan, RW; Csernansky, JG; Goff, DC; Harms, MP; Javitt, DC; Keefe, RS; McEvoy, JP; McMahon, RP; Marder, SR; Peterson, BS; Lieberman, JA (2013). Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.. Neuropsychopharmacology, 38(7), 1245-1252. [doi]  [abs]
  170. Iwata, Y; Nakajima, S; Uchida, H; Suzuki, T; Keefe, R; Plitman, E; Chung, JK; Caravaggio, F; Gerretsen, P; Mimura, M; Graff-Guerrero, A (2015). Effects of Glutamate Modulators on Cognitive Impairments In Schizophrenia: A Meta-Analysis of Double-Blind Controlled Trials. Biological Psychiatry, 77(9).
  171. Iwata, Y; Nakajima, S; Suzuki, T; Keefe, RSE; Plitman, E; Chung, JK; Caravaggio, F; Mimura, M; Graff-Guerrero, A; Uchida, H (2015). Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.. Mol Psychiatry, 20(10), 1151-1160. [doi]  [abs]
  172. Kim, JL; Rele, S; Marks, DM; Masand, PS; Yerramsetty, P; Millet, RA; Keefe, RS; Patkar, AA (2013). Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.. The Primary Care Companion for Cns Disorders, 15(6). [doi]  [abs]
  173. Keefe, RSE; Sweeney, JA; Gu, H; Hamer, RM; Perkins, DO; McEvoy, JP; Lieberman, JA (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.. The American Journal of Psychiatry, 164(7), 1061-1071. [17606658], [doi]  [abs]
  174. Wilson, WH; McEvoy, J; Keefe, R; Byerly, M; Masand, P (2006). Effects of risperidone microspheres on polypharmacy and cognitive function. Neuropsychopharmacology, 31, S178-S178.
  175. Keefe, RSE; Malhotra, AK; Meltzer, HY; Kane, JM; Buchanan, RW; Murthy, A; Sovel, M; Li, C; Goldman, R (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.. Neuropsychopharmacology, 33(6), 1217-1228. [17625502], [doi]  [abs]
  176. Madhoo, M; Keefe, RSE; Roth, RM; Sambunaris, A; Wu, J; Trivedi, MH; Anderson, CS; Lasser, R (2012). Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder. The International Journal of Neuropsychopharmacology, 15, 189-189.
  177. Fleischhacker, WW; Podhorna, J; Gröschl, M; Hake, S; Zhao, Y; Huang, S; Keefe, RSE; Desch, M; Brenner, R; Walling, DP; Mantero-Atienza, E; Nakagome, K; Pollentier, S (2021). Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.. Lancet Psychiatry, 8(3), 191-201. [doi]  [abs]
  178. Kane, JM; D'Souza, DC; Patkar, AA; Youakim, JM; Tiller, J; Yang, R; Keefe, RS (2009). EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA. Schizophrenia Bulletin, 35, 356-357.
  179. Keefe, R; Mahableshwarkar, A; Zajecka, J; Jacobson, W; Chen, Y (2014). Efficacy of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: Cognitive Test Performance Results: from a Randomized, Double-blind, Duloxetine-referenced, Placebo-controlled. Neuropsychopharmacology, 39, S389-S390.
  180. Hill, SK; Sweeney, JA; Hamer, RM; Keefe, RS; Perkins, DO; Gu, H; Koch, G; McEvoy, JP; Lieberman, JA (2007). Efficiency of the BACS and CATIE neuropsychological batteries in assessing cognition and antipsychotic treatment related change in cognition during the CAFE clinical trial. Schizophrenia Bulletin, 33(2), 561-561.
  181. Hill, SK; Sweeney, JA; Hamer, RM; Keefe, RSE; Perkins, DO; Gu, H; McEvoy, JP; Lieberman, JA (2008). Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.. J Int Neuropsychol Soc, 14(2), 209-221. [doi]  [abs]
  182. Reilly, JL; Frankovich, K; Hill, S; Gershon, ES; Keefe, RSE; Keshavan, MS; Pearlson, GD; Tamminga, CA; Sweeney, JA (2014). Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories.. Schizophrenia Bulletin, 40(5), 1011-1021. [doi]  [abs]
  183. Keefe, RS; Harvey, PD; Lenzenweger, MF; Davidson, M; Apter, SH; Schmeidler, J; Mohs, RC; Davis, KL (1992). Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms.. Psychiatry Research, 44(2), 153-165. [doi]  [abs]
  184. Harvey, PD; Lenzenweger, MF; Keefe, RS; Pogge, DL; Serper, MR; Mohs, RC (1992). Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder.. Psychiatry Research, 44(2), 141-151. [doi]  [abs]
  185. Harvey, PD; Davidson, M; White, L; Keefe, RS; Hirschowitz, J; Mohs, RC; Davis, KL (1996). Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.. Biological Psychiatry, 40(8), 755-760. [doi]  [abs]
  186. Resnick, SG; Rosenheck, RA; Canive, JM; De Souza, C; Stroup, TS; McEvoy, J; Davis, S; Keefe, RSE; Swartz, M; Lieberman, J (2008). Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.. J Behav Health Serv Res, 35(2), 215-225. [doi]  [abs]
  187. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2009). Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)). The Australian and New Zealand Journal of Psychiatry, 43(10), 983. [doi]
  188. Krishnan, RR; Fivaz, M; Kraus, MS; Keefe, RSE (2012). Erratum: Hierarchical temporal processing deficit model of reality distortion and psychoses (Molecular Psychiatry (2011) 16, (129-144) DOI: 10.1038/mp.2010.63). Molecular Psychiatry, 17(4), 470. [doi]
  189. Pinheiro, AP; Keefe, RSE; Skelly, T; Olarte, M; Leviel, K; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Sullivan, PF (2009). Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)). The Australian and New Zealand Journal of Psychiatry, 43(11), 1087. [doi]
  190. Lam, M; Wang, M; Huang, W; Eng, GK; Rapisarda, A; Kraus, M; Kang, S; Keefe, RSE; Lee, J (2017). Establishing the Brief Assessment of Cognition - Short form.. J Psychiatr Res, 93, 1-11. [doi]  [abs]
  191. Polanczyk, G; Moffitt, TE; Arseneault, L; Cannon, M; Ambler, A; Keefe, RSE; Houts, R; Odgers, CL; Caspi, A (2010). Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.. Arch Gen Psychiatry, 67(4), 328-338. [20368509], [doi]  [abs]
  192. Seccomandi, B; Agbedjro, D; Keefe, RSE; Galderisi, S; Fiszdon, J; Mucci, A; Wykes, T; Cella, M (2022). Evaluating how treatment adherence influences cognitive remediation outcomes.. Behav Res Ther, 158, 104186. [doi]  [abs]
  193. Mahncke, HW; Kim, S-J; Rose, A; Stasio, C; Buckley, P; Caroff, S; Duncan, E; Yasmin, S; Jarskog, LF; Lamberti, JS; Nuechterlein, K; Strassnig, M; Velligan, D; Ventura, J; Walker, T; Stroup, TS; Keefe, RSE (2019). Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.. Schizophrenia Research, 208, 182-189. [doi]  [abs]
  194. Bauer, IE; Keefe, RSE; Sanches, M; Suchting, R; Green, CE; Soares, JC (2015). Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).. J Psychiatr Res, 60, 81-86. [doi]  [abs]
  195. Javitt, DC; Buchanan, RW; Lieberman, JA; Keefe, RS; Marder, SR (2009). EVALUATION OF THE EFFECTS OF AL-108 ON NEUROCOGNITION IN SCHIZOPHRENIA: INITIAL TURNS STUDY RESULTS. Schizophrenia Bulletin, 35, 365-366.
  196. Brown, D; Nakagome, K; Cordes, J; Brenner, R; Gründer, G; Keefe, RSE; Riesenberg, R; Walling, DP; Daniels, K; Wang, L; McGinniss, J; Sand, M (2019). Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.. Schizophrenia Bulletin, 45(2), 350-359. [doi]  [abs]
  197. Yong, E; Barbato, M; Penn, DL; Keefe, RSE; Woods, SW; Perkins, DO; Addington, J (2014). Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.. Psychiatry Research, 218(1-2), 39-43. [doi]  [abs]
  198. Seccomandi, B; Agbedjro, D; Bell, M; Keefe, RSE; Keshavan, M; Galderisi, S; Fiszdon, J; Mucci, A; Cavallaro, R; Ojeda, N; Peña, J; Müller, D; Roder, V; Wykes, T; Cella, M (2021). Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia.. Schizophrenia Research, 228, 29-35. [doi]  [abs]
  199. Miller, DD; Caroff, SN; Davis, SM; Rosenheck, RA; McEvoy, JP; Saltz, BL; Riggio, S; Chakos, MH; Swartz, MS; Keefe, RSE; Stroup, TS; Lieberman, JA; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial.. Br J Psychiatry, 193(4), 279-288. [18827289], [doi]  [abs]
  200. Siever, LJ; Friedman, L; Moskowitz, J; Mitropoulou, V; Keefe, R; Roitman, SL; Merhige, D; Trestman, R; Silverman, J; Mohs, R (1994). Eye movement impairment and schizotypal psychopathology.. The American Journal of Psychiatry, 151(8), 1209-1215. [doi]  [abs]
  201. Siever, LJ; Keefe, R; Bernstein, DP; Coccaro, EF; Klar, HM; Zemishlany, Z; Peterson, AE; Davidson, M; Mahon, T; Horvath, T (1990). Eye tracking impairment in clinically identified patients with schizotypal personality disorder.. The American Journal of Psychiatry, 147(6), 740-745. [doi]  [abs]
  202. Keefe, RS; Silverman, JM; Mohs, RC; Siever, LJ; Harvey, PD; Friedman, L; Roitman, SE; DuPre, RL; Smith, CJ; Schmeidler, J; Davis, KL (1997). Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia.. Archives of General Psychiatry, 54(2), 169-176. [doi]  [abs]
  203. Keefe, RS; Siever, LJ; Mohs, RC; Peterson, AE; Mahon, TR; Bergman, RL; Davis, KL (1989). Eye tracking, schizophrenic symptoms, and schizotypal personality disorder.. European Archives of Psychiatry and Neurological Sciences, 239(1), 39-42. [doi]  [abs]
  204. Harvey, PD; Horan, WP; Atkins, AS; Stevens, H; Welch, M; Yuan, J; Patterson, TL; Narasimhan, M; Keefe, RSE (2020). Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures.. Schizophrenia Research, 223, 297-304. [doi]  [abs]
  205. Yang, Z; Lim, K; Lam, M; Keefe, R; Lee, J (2018). Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis.. Schizophrenia Research, 201, 85-90. [doi]  [abs]
  206. Keefe, R (2011). FAILURES IN LEARNING- DEPENDENT PREDICTIVE PERCEPTION AS THE KEY VULNERABILITY TO PSYCHOSIS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 37, 17-18.
  207. Keefe, RSE; Kraus, MS; Krishnan, RR (2011). Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.. Neuropsychopharmacology, 36(1), 367-368. [doi]
  208. Silverman, JM; Mohs, RC; Davidson, M; Losonczy, MF; Keefe, RS; Breitner, JC; Sorokin, JE; Davis, KL (1987). Familial schizophrenia and treatment response.. The American Journal of Psychiatry, 144(10), 1271-1276. [doi]  [abs]
  209. Keefe, RSE; Vinogradov, S; Medalia, A; Buckley, PF; Caroff, SN; D'Souza, DC; Harvey, PD; Graham, KA; Hamer, RM; Marder, SM; Miller, DD; Olson, SJ; Patel, JK; Velligan, D; Walker, TM; Haim, AJ; Stroup, TS (2012). Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.. The Journal of Clinical Psychiatry, 73(7), 1016-1022. [doi]  [abs]
  210. Keefe, R; Vinogradov, S; Medalia, A; Buckley, P; Caroff, S; D'Souza, D; Harvey, P; Graham, K; Marder, S; Miller, D; Olson, S; Patel, J; Velligan, D; Walker, T; Haim, A; Stroup, S (2010). FEASIBILITY STUDY OF MULTI-SITE COGNITIVE REMEDIATION IN THE SCHIZOPHRENIA TRIALS NETWORK (CRSTN). Schizophrenia Research, 117(2-3), 394-394. [doi]
  211. Lam, M; Eng, GK; Rapisarda, A; Subramaniam, M; Kraus, M; Keefe, RSE; Collinson, SL (2013). Formulation of the age-education index: measuring age and education effects in neuropsychological performance.. Psychol Assess, 25(1), 61-70. [Gateway.cgi], [doi]  [abs]
  212. Keefe, RSE; Silverman, JM; Amin, F; Lees, SE; Duncan, A; Harvey, PD; Davidson, M; Siever, LJ; Mohs, RC; Davis, KL (1992). Frontal functioning and plasma HVA in the relatives of schizophrenic patients. Schizophrenia Research, 6(2), 158-158. [doi]
  213. Nuechterlein, K; Tishler, T; Ellingson, B; Ventura, J; Williamson, D; Turkoz, I; Keefe, R; O'Donnell, A; Alphs, L (2020). Frontal Intracortical Myelin Volume is Related to Speed of Processing in Patients With First-Episode Schizophrenia Assessed With the MATRICS Consensus Cognitive Battery (MCCB). Neuropsychopharmacology, 45(SUPPL 1), 336-337.
  214. Keefe, R; Hurley, K; Kraus, M; Leech, D; Harvey, P; Walker, T; Loebel, AD; Krishnan, R; Roscigno, R; Pietrobon, R (2009). FUNCTIONAL CAPACITY ASSESSMENTS FOR SCHIZOPHRENIA CLINICAL TRIALS. Schizophrenia Bulletin, 35, 316-316.
  215. Green, MF; Nuechterlein, KH; Kern, RS; Baade, LE; Fenton, WS; Gold, JM; Keefe, RSE; Mesholam-Gately, R; Seidman, LJ; Stover, E; Marder, SR (2008). Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.. The American Journal of Psychiatry, 165(2), 221-228. [doi]  [abs]
  216. Mohs, RC; Alaka, KJ; Keefe, RSE; Purdon, SE; Rock, SL; Wei, H; Marquez, EM; Ahmed, S (2004). Functional outcomes and characteristics of olanzapine cognitive super-responders. Schizophrenia Research, 67(1), 207-208.
  217. Keefe, RSE; Harvey, PD; Goldberg, TE; Gold, JM; Walker, TM (2007). General and specific cognitive deficits in bipolar depression: the Brief Assessment of Cognition in Affective Disorders (BAC-A). Bipolar Disorders, 9, 9-9.
  218. Reilly, JL; Hill, S; Rubin, LH; Ruocco, A; Keefe, R; Keshavan, MS; Pearlson, G; Tamminga, C; Sweeney, JA (2015). GENERALIZED AND SPECIFIC COGNITIVE DEFICITS ACROSS THE PSYCHOSIS SPECTRUM. Schizophrenia Bulletin, 41, S94-S94.
  219. Bishop, J; Hill, S; Mills, L; Alliey-Rodriguez, N; Reilly, J; Shaffee, R; McCarroll, S; Keefe, R; Pearlson, G; Clementz, B; Tamminga, C; Keshavan, M; Gershon, E; Sweeney, J (2017). GENETIC ANALYSES OF COGNITIVE PERFORMANCE IN PSYCHOTIC DISORDERS FROM THE BIPOLAR-SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP) CONSORTIUM. Schizophrenia Bulletin, 43, S245-S245.
  220. Bishop, J; Mills, L; Hill, S; Alliey-Rodriguez, N; Reilly, J; Nanda, P; Padmanabhan, J; Tandon, N; Shafee, R; McCarroll, S; Hyman, S; Keefe, R; Pearlson, G; Clementz, B; Tamminga, C; Keshavan, M; Gershon, E; Sweeney, J (2016). Genetic Associations With Cognitive Performance in Psychotic Disorders From the Bipolar-Schizophrenia Network on Intermediate Phenotypes Consortium. Neuropsychopharmacology, 41, S595-S596.
  221. Xavier, RM; Vorderstrasse, A; Keefe, RSE; Dungan, JR (2018). Genetic correlates of insight in schizophrenia.. Schizophrenia Research, 195, 290-297. [doi]  [abs]
  222. Eum, S; Hill, SK; Alliey-Rodriguez, N; Stevenson, JM; Rubin, LH; Lee, AM; Mills, LJ; Reilly, JL; Lencer, R; Keedy, SK; Ivleva, E; Keefe, RSE; Pearlson, GD; Clementz, BA; Tamminga, CA; Keshavan, MS; Gershon, ES; Sweeney, JA; Bishop, JR (2021). Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.. Neuropsychopharmacology, 46(10), 1802-1810. [doi]  [abs]
  223. McClay, JL; Adkins, DE; Aberg, K; Bukszár, J; Khachane, AN; Keefe, RSE; Perkins, DO; McEvoy, JP; Stroup, TS; Vann, RE; Beardsley, PM; Lieberman, JA; Sullivan, PF; van den Oord, EJCG (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.. Neuropsychopharmacology, 36(3), 616-626. [doi]  [abs]
  224. Keefe, R; Mohamed, S; Siu, C; Rosenheck, R; Fox, K; Lowe, DA; Garibaldi, G; Santarelli, L; Murray, S (2009). GLOBAL COGNITIVE MEASURES AS PRIMARY OUTCOMES IN TREATMENT TRIALS. Schizophrenia Bulletin, 35, 249-250.
  225. Stout, JC; Queller, S; Baker, KN; Cowlishaw, S; Sampaio, C; Fitzer-Attas, C; Borowsky, B; HD-CAB Investigators, (2014). HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.. Mov Disord, 29(10), 1281-1288. [doi]  [abs]
  226. Krishnan, RR; Fivaz, M; Kraus, MS; Keefe, RSE (2011). Hierarchical temporal processing deficit model of reality distortion and psychoses.. Mol Psychiatry, 16(2), 129-144. [doi]  [abs]
  227. Keefe, RSE; Fenton, WS (2010). HOW SHOULD DSM-V CRITERIA FOR SCHIZOPHRENIA INCLUDE COGNITIVE IMPAIRMENT?. DECONSTRUCTING PSYCHOSIS: REFINING THE RESEARCH AGENDA FOR DSM-V, 83-98.
  228. Keefe, RSE; Fenton, WS (2007). How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bulletin, 33(4), 912-920. [doi]  [abs]
  229. Cruz, BF; de Resende, CB; Abreu, MN; Rocha, FL; Teixeira, AL; Keefe, RSE; Salgado, JV (2013). How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.. Cogn Neuropsychiatry, 18(3), 243-251. [doi]  [abs]
  230. Rekhi, G; Saw, YE; Lim, K; Keefe, RSE; Lee, J (2023). Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia.. Brain Sciences, 13(2). [doi]  [abs]
  231. Epstein, JI; Keefe, RS; Roitman, SL; Harvey, PD; Mohs, RC (1996). Impact of neuroleptic medications on continuous performance test measures in schizophrenia.. Biological Psychiatry, 39(10), 902-905. [doi]
  232. Zhang, L; Hill, SK; Guo, B; Wu, B; Alliey-Rodriguez, N; Eum, S; Lizano, P; Ivleva, EI; Reilly, JL; Keefe, RSE; Keedy, SK; Tamminga, CA; Pearlson, GD; Clementz, BA; Keshavan, MS; Gershon, ES; Sweeney, JA; Bishop, JR (2022). Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.. Prog Neuropsychopharmacol Biol Psychiatry, 113, 110464. [doi]  [abs]
  233. Lim, J; Rekhi, G; Rapisarda, A; Lam, M; Kraus, M; Keefe, RSE; Lee, J (2015). Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).. Schizophrenia Research, 164(1-3), 8-14. [doi]  [abs]
  234. Kraus, M; Walker, T; Jarskog, F; Keefe, R (2015). IMPAIRED AUDITORY PERCEPTION AND EMOTION IDENTIFICATION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 41, S84-S85.
  235. Lindenmayer, J-P; Khan, A; Harvey, P; Keefe, R; Liharska, L; Yavorsky, C; Seddo, M (2020). IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. Schizophrenia Bulletin, 46, S180-S181.
  236. Reilly, JL; Hill, SK; Gold, JM; Keefe, RSE; Clementz, BA; Gershon, E; Keshavan, MS; Pearlson, G; Tamminga, CA; Sweeney, JA (2017). Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder.. Schizophrenia Bulletin, 43(2), 397-406. [doi]  [abs]
  237. Keefe, RSE; Harvey, PD (2008). Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.. Schizophrenia Bulletin, 34(4), 656-663. [doi]  [abs]
  238. Yurgelun-Todd, DA; Renshaw, PF; Wei, H; Keefe, RSE; Charles, HC; Tohen, M; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Gur, RC; Tollefson, GD; Lieberman, JA (2003). Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis. Biological Psychiatry, 53(8), 156S-156S.
  239. Yurgelun-Todd, DA; Renshaw, PF; Wei, H; Keefe, RS; Charles, HC; Tohen, M; Liebermann, JA (2003). Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis. Schizophrenia Research, 60(1), 318-318. [doi]
  240. Siever, LJ; Silverman, JM; Horvath, TB; Klar, H; Coccaro, E; Keefe, RS; Pinkham, L; Rinaldi, P; Mohs, RC; Davis, KL (1990). Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients.. Archives of General Psychiatry, 47(7), 634-640. [doi]  [abs]
  241. Keefe, RSE (2009). Increasing sensitivity of early detection of psychosis with cognitive measures. International Journal of Psychiatry in Clinical Practice, 13, 7-7.
  242. Rosenbaum, J; Keefe, R; Lieberman, J; Romano, S; McKinney, R; Orf, H (2014). Industry and Academic Science: Can Academia Work More Effectively and Ethically with Industry to Get New Therapies to the Market?. Neuropsychopharmacology, 39, S37-S38.
  243. Harvey, PD; Keefe, RSE; Mitroupolou, V; DuPre, R; Roitman, SL; Mohs, RC; Siever, LJ (1996). Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research, 60(1), 49-56. [doi]  [abs]
  244. Lutz, J; Pratap, A; Lenze, EJ; Bestha, D; Lipschitz, JM; Karantzoulis, S; Vaidyanathan, U; Robin, J; Horan, W; Brannan, S; Mittoux, A; Davis, MC; Lakhan, SE; Keefe, R (2023). Innovative Technologies in CNS Trials: Promises and Pitfalls for Recruitment, Retention, and Representativeness. Innovations in Clinical Neuroscience, 20(7-9), 40-46.  [abs]
  245. McEvoy, JP; Johnson, J; Perkins, D; Lieberman, JA; Hamer, RM; Keefe, RSE; Tohen, M; Glick, ID; Sharma, T (2006). Insight in first-episode psychosis.. Psychological Medicine, 36(10), 1385-1393. [16740175], [doi]  [abs]
  246. Sim, K; Lee, J; Subramaniam, M; Liu, JJ; Keefe, R; Zhang, XD; Lee, TS; Chong, SA (2011). Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview.. Early Interv Psychiatry, 5(2), 91-99. [doi]  [abs]
  247. Chwastiak, LA; Rosenheck, RA; McEvoy, JP; Keefe, RS; Swartz, MS; Lieberman, JA (2006). Interrelationships of psychiatric symptom severity, medical comorbidity and functional status in patients with schizophrenia. Journal of General Internal Medicine, 21, 76-76.
  248. Chwastiak, LA; Rosenheck, RA; McEvoy, JP; Keefe, RS; Swartz, MS; Lieberman, JA (2006). Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.. Psychiatric Services (Washington, D.C.), 57(8), 1102-1109. [16870960], [doi]  [abs]
  249. Vita, A; Deste, G; Barlati, S; De Peri, L; Giambra, A; Poli, R; Keefe, RSE; Sacchetti, E (2013). Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.. Schizophrenia Research, 146(1-3), 217-223. [doi]  [abs]
  250. Cruz, BF; Resende, CBD; Carvalhaes, CF; Cardoso, CS; Teixeira, AL; Keefe, RS; Rocha, FL; Salgado, JV (2016). Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.. Braz J Psychiatry, 38(3), 216-221. [doi]  [abs]
  251. Lee, S-A; Lam, M; Rapisarda, A; Kraus, M; Keefe, R; Lee, J (2015). INVESTIGATING THE STRUCTURE OF SEMANTIC ORGANIZATION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 41, S85-S85.
  252. Marquez, EM; Keefe, RS; Purdon, SE; Rock, SL; Alaka, K; Ahmed, S; Mohs, RC (2004). Is cognitive improvement with antipsychotic treatment pseudospecific?. The International Journal of Neuropsychopharmacology, 7, S394-S394.
  253. Marquez, EM; Keefe, RSE; Purdon, SE; Rock, SL; Alaka, KJ; Ahmed, S; Mohs, RC (2004). Is cognitive improvement with antipsychotic treatment pseudospecific?. Schizophrenia Research, 67(1), 207-207.
  254. Marder, SR; Alphs, L; Anghelescu, I-G; Arango, C; Barnes, TRE; Caers, I; Daniel, DG; Dunayevich, E; Fleischhacker, WW; Garibaldi, G; Green, MF; Harvey, PD; Kahn, RS; Kane, JM; Keefe, RSE; Kinon, B; Leucht, S; Lindenmayer, J-P; Malhotra, AK; Stauffer, V; Umbricht, D; Wesnes, K; Kapur, S; Rabinowitz, J (2013). Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.. Schizophrenia Research, 150(2-3), 328-333. [doi]  [abs]
  255. Frecska, E; Losonczy, M; Keefe, RSE; Silverman, JM; Davidson, M; Harvey, P; McQueeney, RT; Lobel, D; Apter, S; Davis, KL (1991). Kraepelinian schizophrenia: A replication in an independent sample. Schizophrenia Research, 4(3), 257-257. [doi]
  256. Keefe, RS; Mohs, RC; Davidson, M; Losonczy, MF; Silverman, JM; Lesser, JC; Horvath, TB; Davis, KL (1988). Kraepelinian schizophrenia: a subgroup of schizophrenia?. Psychopharmacology Bulletin, 24(1), 56-61.
  257. Davidson, M; Keefe, RS; Mohs, RC; Siever, LJ; Losonczy, MF; Horvath, TB; Davis, KL (1987). L-dopa challenge and relapse in schizophrenia.. The American Journal of Psychiatry, 144(7), 934-938. [doi]  [abs]
  258. Keefe, RSE; Roitman, SEL; Dupre, RL; Harvey, PD (1996). Laboratory and clinical tests of spatial working memory. Schizophrenia Research, 18(2-3), XIII7-XIII7.
  259. Klauser, P; Zhou, J; Lim, JKW; Poh, JS; Zheng, H; Tng, HY; Krishnan, R; Lee, J; Keefe, RSE; Adcock, RA; Wood, SJ; Fornito, A; Chee, MWL (2015). Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study.. Schizophrenia Bulletin, 41(6), 1285-1293. [doi]  [abs]
  260. Goff, DC; Keefe, R; Citrome, L; Davy, K; Krystal, JH; Large, C; Thompson, TR; Volavka, J; Webster, EL (2007). Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.. Journal of Clinical Psychopharmacology, 27(6), 582-589. [doi]  [abs]
  261. Wang, C; Lee, J; Ho, NF; Lim, JKW; Poh, JS; Rekhi, G; Krishnan, R; Keefe, RSE; Adcock, RA; Wood, SJ; Fornito, A; Chee, MWL; Zhou, J (2018). Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study.. Cerebral Cortex, 28(12), 4234-4243. [doi]  [abs]
  262. Healey, KM; Penn, DL; Perkins, D; Woods, SW; Keefe, RSE; Addington, J (2018). Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction.. Schizophrenia Bulletin, 44(2), 286-296. [doi]  [abs]
  263. McCleery, A; Green, MF; Hellemann, GS; Baade, LE; Gold, JM; Keefe, RSE; Kern, RS; Mesholam-Gately, RI; Seidman, LJ; Subotnik, KL; Ventura, J; Nuechterlein, KH (2016). Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).. Psychol Med, 46(5), 1119. [doi]
  264. McCleery, A; Green, MF; Hellemann, GS; Baade, LE; Gold, JM; Keefe, RSE; Kern, RS; Mesholam-Gately, RI; Seidman, LJ; Subotnik, KL; Ventura, J; Nuechterlein, KH (2015). Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).. Psychol Med, 45(12), 2657-2666. [doi]  [abs]
  265. Yehuda, R; Keefe, RS; Harvey, PD; Levengood, RA; Gerber, DK; Geni, J; Siever, LJ (1995). Learning and memory in combat veterans with posttraumatic stress disorder.. The American Journal of Psychiatry, 152(1), 137-139. [doi]  [abs]
  266. Vocisano, C; Klein, DN; Keefe, RS (1997). Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder.. Psychiatry Research, 73(1-2), 33-45. [doi]  [abs]
  267. Nasrallah, HA; Keefe, R; Lasser, R; Dirks, B; Kirsch, C; Wang, J; Scheckner, B; Lindenmayer, J-P (2012). Lisdexamfetamine Dimesylate as Adjunctive Treatment with Antipsychotics for Predominant Negative Symptoms of Schizophrenia: Concurrent Neurocognitive and Negative Symptom Improvement. Biological Psychiatry, 71(8), 65S-65S.
  268. Madhoo, M; Keefe, RSE; Roth, RM; Sambunaris, A; Wu, J; Trivedi, MH; Anderson, CS; Lasser, R (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.. Neuropsychopharmacology, 39(6), 1388-1398. [doi]  [abs]
  269. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Sharma, T; Sitskoorn, MM; Rock, SL; Woolson, S; Tohen, M; Tollefson, GD; Sanger, TM; Lieberman, JA; HGDH Research Group, (2006). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.. Biological Psychiatry, 59(2), 97-105. [16140282], [doi]  [abs]
  270. Apter, SH; Keefe, RSE; Hirschowitz, J; Davidson, M; Macaluso, JM; Amato, R; Davis, KL (1994). Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies. Biological Psychiatry, 35(9), 695-695. [doi]
  271. Lam, M; Lee, J; Rapisarda, A; See, YM; Yang, Z; Lee, S-A; Abdul-Rashid, NA; Kraus, M; Subramaniam, M; Chong, S-A; Keefe, RSE (2018). Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.. Jama Psychiatry, 75(9), 929-939. [doi]  [abs]
  272. Stroup, TS; Appelbaum, PS; Gu, H; Hays, S; Swartz, MS; Keefe, RSE; Kim, SY; Manschreck, TC; Boshes, RA; McEvoy, JP; Lieberman, JA (2011). Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.. Schizophrenia Research, 130(1-3), 47-52. [doi]  [abs]
  273. Lee, J; Rapisarda, A; Kraus, M; Chong, S-A; Keefe, R (2012). LONGITUDINAL YOUTH-AT-RISK STUDY (LYRIKS): EXAMINING THE PRODROME FROM ANOTHER PERSPECTIVE. Schizophrenia Research, 136, S308-S309.
  274. Keefe, R; Davis, V; Atkins, A; Harvey, P; Hilt, D; Lombardo, I; Bugarski-Kirola, D; Reid, C (2015). Magnitude and Predictors of MATRICS Consensus Cognitive Battery Change in Placebo Treated Patients with Schizophrenia. Biological Psychiatry, 77(9), 1 pages.
  275. Davidson, M; Kahn, RS; Stern, RG; Harvey, PD; Keefe, R; Knott, P; Apter, S; Webster, L; Davis, KL (1992). Measurements of plasma homovanillic acid in schizophrenic patients.. Clinical Neuropharmacology, 15 Suppl 1 Pt A, 521A-522A. [doi]
  276. Keefe, RSE (2006). Measures of cognitive change in schizophrenia clinical trials. The International Journal of Neuropsychopharmacology, 9, S48-S48.
  277. Keefe, RSE; Kraus, MS (2009). Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia.. Ann Acad Med Singap, 38(5), 414-416.  [abs]
  278. Rosenheck, R; Stroup, S; Keefe, RSE; McEvoy, J; Swartz, M; Perkins, D; Hsiao, J; Shumway, M; Lieberman, J (2005). Measuring outcome priorities and preferences in people with schizophrenia.. The British Journal of Psychiatry : the Journal of Mental Science, 187(DEC.), 529-536. [doi]  [abs]
  279. Kraus, MS; Keefe, RSE; Krishnan, RKR (2009). Memory-prediction errors and their consequences in schizophrenia.. Neuropsychol Rev, 19(3), 336-352. [doi]  [abs]
  280. Marder, SR; Daniel, DG; Alphs, L; Awad, AG; Keefe, RSE (2011). Methodological issues in negative symptom trials.. Schizophrenia Bulletin, 37(2), 250-254. [doi]  [abs]
  281. Harvey, PD; Keefe, RSE (2015). Methods for delivering and evaluating the efficacy of cognitive enhancement.. Handbook of Experimental Pharmacology, 228, 5-25. [doi]  [abs]
  282. Meier, MH; Shalev, I; Moffitt, TE; Kapur, S; Keefe, RSE; Wong, TY; Belsky, DW; Harrington, H; Hogan, S; Houts, R; Caspi, A; Poulton, R (2013). Microvascular abnormality in schizophrenia as shown by retinal imaging.. American Journal of Psychiatry, 170(12), 1451-1459. [24030514], [doi]  [abs]
  283. Keefe, RSE (2006). Missing the sweet spot disengagement in schizophrenia.. Psychiatry (Edgmont (Pa. : Township)), 3(7), 36-41.  [abs]
  284. Buchanan, RW; Barch, D; Csernansky, J; Goff, D; Gold, J; Jarskog, F; Javitt, D; Keefe, R; Lieberman, J; McEvoy, J; McMahon, R; Marder, S (2010). MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA. Schizophrenia Research, 117(2-3), 119-119. [doi]
  285. Davidson, M; Reichenberg, AA; Levine, SZ; Rabinowitz, J; Keefe, R; Murray, R; Moffitt, T; Caspi, A (2011). MODELING THE EXPRESSION AND COURSE OF DEVELOPMENTAL ABNORMALITIES PRECEDING ADULT SCHIZOPHRENIA: CHARACTERIZATION OF A NEW DEVELOPMENTAL ULTRA-HIGH-RISK GROUP IN 2 BIRTH COHORTS. Schizophrenia Bulletin, 37, 49-50.
  286. Sullivan, PF; Keefe, RSE; Lange, LA; Lange, EM; Stroup, TS; Lieberman, J; Maness, PF (2007). NCAM1 and neurocognition in schizophrenia.. Biological Psychiatry, 61(7), 902-910. [doi]  [abs]
  287. Khan, A; Liharska, L; Harvey, PD; Atkins, A; Ulshen, D; Keefe, RSE (2017). Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency.. Innovations in Clinical Neuroscience, 14(11-12), 30-40.  [abs]
  288. Keefe, RSE (2010). Neurocognition, 97-119. [doi]  [abs]
  289. Keefe, RSE; Mohs, RC; Bilder, RM; Harvey, PD; Green, MF; Meltzer, HY; Gold, JM; Sano, M (2003). Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.. Schizophrenia Bulletin, 29(1), 45-55. [doi]  [abs]
  290. Keefe, R; Bilder, RM; Davis, SM; Harvey, PD; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Capuano, G; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Davis, CE; Hsiao, JK; Lieberman, JA (2006). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Neuropsychopharmacology, 31, S244-S245.
  291. Keefe, RSE; Bilder, RM; Davis, SM; Harvey, PD; Palmer, BW; Gold, JM; Meltzer, HY; Green, MF; Capuano, G; Stroup, TS; McEvoy, JP; Swartz, MS; Rosenheck, RA; Perkins, DO; Davis, CE; Hsiao, JK; Lieberman, JA; CATIE Investigators, ; Neurocognitive Working Group, (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.. Archives of General Psychiatry, 64(6), 633-647. [17548746], [doi]  [abs]
  292. Keefe, RSE; Seidman, LJ; Christensen, B; Hamer, RM; Yurgelun-Todd, D (2004). Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis. Schizophrenia Research, 67(1), 206-206.
  293. Keefe, RSE; Seidman, LJ; Christensen, BK; Hamer, RM; Yurgelun-Todd, DA; Lewine, RRJ; Sitskoorn, MM; Sharma, T; Tohen, M; Lieberman, JA (2003). Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis. Biological Psychiatry, 53(8), 26S-26S.
  294. Keefe, R; Seidman, LJ; Christensen, B; Hamer, RM; Yurgelun-Todd, D; Lewine, R; Sitskoorn, M; Sharma, T; Tohen, M; Lieberman, JA (2003). Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis. Schizophrenia Research, 60(1), 289-289. [doi]
  295. Perkins, D; Gu, HB; Zipursky, RB; Christensen, BK; Dixon, V; Keefe, RS (2004). Neurocognitive function in individuals "at-risk" for psychosis. Neuropsychopharmacology, 29, S220-S220.
  296. Epstein, JI; Keefe, RSE; Lees Roitman, SE; Harvey, PD; Davidson, M; Siever, LJ; Mohs, RC (1994). Neuroleptic effects on CPT and eye tracking in schizophrenia. Biological Psychiatry, 35(9), 674-674. [doi]
  297. Kahn, RS; Harvey, PD; Davidson, M; Keefe, RS; Apter, S; Neale, JM; Mohs, RC; Davis, KL (1994). Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function.. Schizophrenia Research, 11(3), 217-224. [doi]  [abs]
  298. Hawkins, KA; Keefe, RSE; Christensen, BK; Addington, J; Woods, SW; Callahan, J; Zipursky, RB; Perkins, DO; Tohen, M; Breier, A; McGlashan, TH (2008). Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.. Schizophrenia Research, 105(1-3), 1-9. [doi]  [abs]
  299. Meier, MH; Caspi, A; Reichenberg, A; Keefe, RSE; Fisher, HL; Harrington, H; Houts, R; Poulton, R; Moffitt, TE (2014). Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.. American Journal of Psychiatry, 171(1), 91-101. [doi]  [abs]
  300. Hill, SK; Reilly, JL; Keefe, RSE; Gold, JM; Bishop, JR; Gershon, ES; Tamminga, CA; Pearlson, GD; Keshavan, MS; Sweeney, JA (2013). Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.. American Journal of Psychiatry, 170(11), 1275-1284. [Gateway.cgi], [doi]  [abs]
  301. Hawkins, KA; Addington, J; Keefe, RSE; Christensen, B; Perkins, DO; Zipurksy, R; Woods, SW; Miller, TJ; Marquez, E; Breier, A; McGlashan, TH (2004). Neuropsychological status of subjects at high risk for a first episode of psychosis.. Schizophrenia Research, 67(2-3), 115-122. [doi]  [abs]
  302. Seidman, LJ; Giuliano, AJ; Meyer, EC; Addington, J; Cadenhead, KS; Cannon, TD; McGlashan, TH; Perkins, DO; Tsuang, MT; Walker, EF; Woods, SW; Bearden, CE; Christensen, BK; Hawkins, K; Heaton, R; Keefe, RSE; Heinssen, R; Cornblatt, BA; North American Prodrome Longitudinal Study (NAPLS) Group, (2010). Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.. Arch Gen Psychiatry, 67(6), 578-588. [doi]  [abs]
  303. Marx, CE; Keefe, RS; Payne, VM; Kilts, JD; Strauss, JL; Naylor, JC; Hamer, RM; Buchanan, RW; Lieberman, JA; Shampine, LJ; Massing, MW (2009). NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD. Schizophrenia Bulletin, 35, 368-368.
  304. Konneker, TI; Crowley, JJ; Quackenbush, CR; Keefe, RSE; Perkins, DO; Stroup, TS; Lieberman, JA; van den Oord, E; Sullivan, PF (2010). No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.. Am J Med Genet B Neuropsychiatr Genet, 153B(5), 1115-1117. [doi]  [abs]
  305. Thaker, G; Moran, M; Cassady, S; Adami, H; Tamminga, C (1991). Normal smooth pursuit eye movements in volunteer subjects meeting schizotypal personality disorder criteria.. The American Journal of Psychiatry, 148(8), 1096-1097.
  306. Sarkisyan, G; Gurovich, I; Keefe, RSE (2011). NORMATIVE DATA FOR RUSSIAN POPULATION AND STANDARDIZATION OF THE SCALE "BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA". European Psychiatry, 26, 1 pages.
  307. Keefe, RSE; Harvey, PD; Goldberg, TE; Gold, JM; Walker, TM; Kennel, C; Hawkins, K (2008). Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).. Schizophrenia Research, 102(1-3), 108-115. [doi]  [abs]
  308. Harvey, P; Khan, A; Atkins, A; Keefe, R (2019). O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS. Schizophrenia Bulletin, 45(Supplement_2), S175-S175. [doi]
  309. Healey, KM; Combs, DR; Gibson, CM; Keefe, RSE; Roberts, DL; Penn, DL (2015). Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.. Cogn Neuropsychiatry, 20(3), 198-221. [doi]  [abs]
  310. Keefe, R; Kraus, M; Dixon, V; Kennel, C; Perkins, D (2008). Olfactory and cognitive function in subjects at ultra-high risk for psychosis. Biological Psychiatry, 63(7), 120S-120S.
  311. Keefe, RSE; Young, CA; Rock, SL; Purdon, SE; Gold, JM; Breier, A; HGGN Study Group, (2006). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.. Schizophrenia Research, 81(1), 1-15. [doi]  [abs]
  312. Woodward, TS; Menon, M; Hu, X; Keefe, RSE (2006). Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring.. Schizophrenia Research, 85(1-3), 106-112. [doi]  [abs]
  313. Sethuraman, G; Ahmed, S; Rock, SL; Young, CA; Marquez, EM; Purdon, SE; Keefe, RSE (2004). P.2.137 Can the PANSS cognitive factor be a validsurrogate for neurocognon in schizophrenia?. European Neuropsychopharmacology, 14, S292-S293. [doi]
  314. Madhoo, M; Roth, RM; Keefe, RSE; Sambunaris, A; Scheckner, B; Nielsen, J; Adeyi, B; Wu, J; Lasser, R (2012). P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels. European Neuropsychopharmacology, 22, S233-S234. [doi]
  315. Keefe, RSE; Mahableshwarkar, AR; Olsen, CK (2013). P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine. European Neuropsychopharmacology, 23, S402-S403. [doi]
  316. Jacobson, W; Olsen, C; Mahableshwarkar, A; Yinzhong, C; Keefe, R (2015). P.2.h.012 Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction. European Neuropsychopharmacology, 25, S460-S460. [doi]
  317. Podhorna, J; Hake, S; Zhao, Y; Groeschl, M; Pollentier, S; Atkins, A; Keefe, R (2019). P.244 Novel endpoints of motivation and reinforcement learning in a large interventional clinical trial of BI 425809 in patients with schizophrenia. European Neuropsychopharmacology, 29, S187-S188. [doi]
  318. Kern, RS; Gold, J; Dickinson, D; Green, M; Nuechterlein, K; Baade, L; Keefe, R; Mesholam-Gately, R; Seidman, L; Marder, S (2009). PATTERNS OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS). Schizophrenia Bulletin, 35, 283-283.
  319. Harvey, PD; Ogasa, M; Cucchiaro, J; Loebel, A; Keefe, R (2009). PERFORMANCE AND INTERVIEW-BASED ASSESSMENTS OF COGNITIVE CHANGE IN A RANDOMIZED, DOUBLE-BLIND COMPARISON OF LURASIDONE VS. ZIPRASIDONE. Schizophrenia Bulletin, 35, 357-357.
  320. Harvey, PD; Ogasa, M; Cucchiaro, J; Loebel, A; Keefe, RSE (2011). Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.. Schizophrenia Research, 127(1-3), 188-194. [doi]  [abs]
  321. Keefe, RS; Silverman, JM; Roitman, SE; Harvey, PD; Duncan, MA; Alroy, D; Siever, LJ; Davis, KL; Mohs, RC (1994). Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests.. Psychiatry Research, 53(1), 1-12. [doi]  [abs]
  322. Keefe, RS; Lees-Roitman, SE; Dupre, RL (1997). Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay.. Schizophrenia Research, 26(1), 9-14. [doi]  [abs]
  323. DEVEGVAR, ML; KEEFE, RSE; MOSKOWITZ, J; LEES, S; KALUS, O; KNOTT, P; TRESTMAN, RL; SIEVER, LJ (1993). PERFORMANCE ON TESTS SENSITIVE TO FRONTAL-LOBE DYSFUNCTION AND DEFICIT-LIKE SYMPTOMS IN SCHIZOTYPAL PERSONALITY-DISORDER. Biological Psychiatry, 33(6A), A101-A101.
  324. Zhang, L; Lizano, P; Xu, Y; Rubin, L; Lee, A; Lencer, R; Reilly, J; Keefe, R; Keedy, S; Pearlson, G; Clementz, B; Keshavan, M; Gershon, E; Tamminga, C; Sweeney, JA; Hill, S; Bishop, J (2022). Peripheral Inflammation is Associated With Impairments of Inhibitory Behavioral Control and Visual Sensorimotor Function in Psychotic Disorders. Neuropsychopharmacology, 47, 380-381.
  325. Zhang, L; Lizano, P; Xu, Y; Rubin, LH; Lee, AM; Lencer, R; Reilly, JL; Keefe, RSE; Keedy, SK; Pearlson, GD; Clementz, BA; Keshavan, MS; Gershon, ES; Tamminga, CA; Sweeney, JA; Hill, SK; Bishop, JR (2023). Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders.. Schizophrenia Research, 255, 69-78. [doi]  [abs]
  326. Meier, MH; Caspi, A; Ambler, A; Harrington, H; Houts, R; Keefe, RSE; McDonald, K; Ward, A; Poulton, R; Moffitt, TE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife.. Proc Natl Acad Sci U S A, 109(40), E2657-E2664. [22927402], [doi]  [abs]
  327. Narendran, R; Frankle, WG; Keefe, RSE; Gil, RB; Martinez, D; Kegeles, LS; Talbot, PS; Huang, YY; Hwang, DR; Keilp, JG; Khenissi, L; Cooper, TB; Caton, C; Laruelle, M; Abi-Dargham, A (2004). PET imaging of prefrontal dopamine D1 receptors in chronic ketamine human abusers: A model for schizophrenia. Biological Psychiatry, 55, 19S-20S.
  328. Need, AC; Keefe, RSE; Ge, D; Grossman, I; Dickson, S; McEvoy, JP; Goldstein, DB (2009). Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.. European Journal of Human Genetics : Ejhg, 17(7), 946-957. [19156168], [doi]  [abs]
  329. Walling, D; Marder, SR; Kane, J; Fleischhacker, WW; Keefe, RSE; Hosford, DA; Dvergsten, C; Segreti, AC; Beaver, JS; Toler, SM; Jett, JE; Dunbar, GC (2016). Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.. Schizophrenia Bulletin, 42(2), 335-343. [doi]  [abs]
  330. Keefe, RSE; Davis, VG; Harvey, PD; Atkins, AS; Haig, GM; Hagino, O; Marder, S; Hilt, DC; Umbricht, D (2017). Placebo Response and Practice Effects in Schizophrenia Cognition Trials.. Jama Psychiatry, 74(8), 807-814. [doi]  [abs]
  331. Cohen, EA; Hassman, HH; Ereshefsky, L; Walling, DP; Grindell, VM; Keefe, RSE; Wyka, K; Horan, WP (2021). Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.. Neuropsychopharmacology, 46(4), 844-850. [doi]  [abs]
  332. Harvey, PD; Davidson, M; Mohs, RC; Keefe, RSE; Moskowitz, J; Knott, P; Duffelmeyer, M (1991). Plasma HVA correlates of attentional performance in unmedicated schizophrenics. Schizophrenia Research, 4(3), 345-346. [doi]
  333. Lam, M; Keefe, R; Jun Liu, J; Lee, J (2017). Pleiotropic Effects of Schizophrenia And Cognitive LOCI: A Meta-Analytic Approach. European Neuropsychopharmacology, 27, S394-S395. [doi]
  334. Supina, D; Endicott, J; Madhoo, M; Keefe, RSE; Trivedi, M; Wu, J; Scheckner, B; Lasser, R (2012). PMH61 Effects of Lisdexamfetamine Dimesylate Augmentation on Functional Outcomes in Adults with Partially or Fully Remitted Major Depressive Disorder. Value in Health, 15(4), A93-A93. [doi]
  335. Shafee, R; Nanda, P; Padmanabhan, JL; Tandon, N; Alliey-Rodriguez, N; Kalapurakkel, S; Weiner, DJ; Gur, RE; Keefe, RSE; Hill, SK; Bishop, JR; Clementz, BA; Tamminga, CA; Gershon, ES; Pearlson, GD; Keshavan, MS; Sweeney, JA; McCarroll, SA; Robinson, EB (2018). Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls.. Translational Psychiatry, 8(1), 78. [doi]  [abs]
  336. Xavier, RM; Dungan, JR; Keefe, RSE; Vorderstrasse, A (2018). Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia.. Schizophrenia Research. Cognition, 12, 11-19. [doi]  [abs]
  337. Colijn, MA; Barbato, M; Keefe, RSE; Perkins, DO; Woods, SW; Addington, J (2012). Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION. Schizophrenia Research, 136, S237-S237. [doi]
  338. Rapisarda, A; Lim, T; Lim, M; Collinson, S; Kraus, M; Keefe, R (2012). Poster #163 APPLICABILITY OF THE MATRICS CONSENSUS COGNITIVE BATTERY IN SINGAPORE. Schizophrenia Research, 136, S150-S150. [doi]
  339. Keefe, RSE; Buchanan, RW; Marder, SR; Schooler, NR; Dugar, A; Zivkov, M; Stewart, M (2012). Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?. Schizophrenia Research, 136, S352-S352. [doi]
  340. Lam, M; Collinson, S; Eng, GK; Rapisarda, A; Kraus, M; Lee, J; Chong, SA; Keefe, R (2014). Poster #M186 NEUROCOGNITIVE ARCHITECTURE OF SCHIZOPHRENIA. Schizophrenia Research, 153, S258-S258. [doi]
  341. Huang, W; Lee, J; Lam, M; Rapisarda, A; Kraus, M; Keefe, R (2014). Poster #S188 THE ROLE OF COGNITIVE RESERVE IN PREDICTING NEUROPSYCHOLOGICAL OUTCOME IN SCHIZOPHRENIA. Schizophrenia Research, 153, S157-S158. [doi]
  342. Lam, M; See, AY; Lee, J; Kang, S; Rapisarda, A; Kraus, M; Keefe, R; Collinson, S (2014). Poster #T129 NEUROCOGNITIVE ARCHITECTURE OF SCHIZOTYPY IN AN ASIAN POPULATION. Schizophrenia Research, 153, S335-S336. [doi]
  343. Hilt, D; Lombardo, I; Gawryl, M; Dgetluck, N; Keefe, R (2014). Poster #T94 OPTIMIZING TREATMENT AND SIGNAL DETECTION WITH EVP-6124 IN A CIAS PHASE 2B STUDY. Schizophrenia Research, 153, S322-S322. [doi]
  344. Keefe, RSE; Reichenberg, A (2016). Predicting Schizophrenia.. Jama Psychiatry, 73(5), 441-442. [doi]
  345. Perkins, DO; Johnson, JL; Hamer, RM; Zipursky, RB; Keefe, RS; Centorrhino, F; Green, AI; Glick, IB; Kahn, RS; Sharma, T; Tohen, M; McEvoy, JP; Weiden, PJ; Lieberman, JA; HGDH Research Group, (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.. Schizophrenia Research, 83(1), 53-63. [doi]  [abs]
  346. Keefe, RS; Mohs, RC; Losonczy, MF; Davidson, M; Silverman, JM; Horvath, TB; Davis, KL (1989). Premorbid sociosexual functioning and long-term outcome in schizophrenia.. The American Journal of Psychiatry, 146(2), 206-211. [doi]  [abs]
  347. Yaakub, SN; Dorairaj, K; Poh, JS; Asplund, CL; Krishnan, R; Lee, J; Keefe, RSE; Adcock, RA; Wood, SJ; Chee, MWL (2013). Preserved working memory and altered brain activation in persons at risk for psychosis.. American Journal of Psychiatry, 170(11), 1297-1307. [Gateway.cgi], [doi]  [abs]
  348. Marx, CE; Lee, J; Subramaniam, M; Rapisarda, A; Bautista, DCT; Chan, E; Kilts, JD; Buchanan, RW; Wai, EP; Verma, S; Sim, K; Hariram, J; Jacob, R; Keefe, RSE; Chong, SA (2014). Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.. Psychopharmacology (Berl), 231(17), 3647-3662. [doi]  [abs]
  349. Marx, CE; Keefe, RSE; Buchanan, RW; Hamer, RM; Kilts, JD; Bradford, DW; Strauss, JL; Naylor, JC; Payne, VM; Lieberman, JA; Savitz, AJ; Leimone, LA; Dunn, L; Porcu, P; Morrow, AL; Shampine, LJ (2009). Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.. Neuropsychopharmacology, 34(8), 1885-1903. [19339966], [doi]  [abs]
  350. Marx, CE; Keefe, RS; Leimone, LA; Hamer, RM; Bradford, DW; Dunn, L; Payne, VM; Naylor, JC; Savitz, AJ; Strauss, JL; Lieberman, JA; Shampine, LJ (2007). Proof-of-concept trial with the neurosterold pregnenolone targeting neurocognitive and negative symptoms in schizophrenia. Biological Psychiatry, 61(8), 13S-13S.
  351. Georgiades, A; Davis, VG; Atkins, AS; Khan, A; Walker, TW; Loebel, A; Haig, G; Hilt, DC; Dunayevich, E; Umbricht, D; Sand, M; Keefe, RSE (2017). Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.. Schizophrenia Research, 190, 172-179. [doi]  [abs]
  352. Lim, C; Chong, SA; Keefe, RSE (2009). Psychosocial factors in the neurobiology of schizophrenia: a selective review.. Ann Acad Med Singap, 38(5), 402-406.  [abs]
  353. Horan, WP; Depp, CA; Hurst, S; Linthicum, J; Vargas, G; Klein, H; Keefe, RSE; Harvey, PD (2023). Qualitative Analysis of the Content Validity of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) in Schizophrenia: A Multi-Stakeholder Perspective. Schizophrenia Bulletin Open, 4(1). [doi]  [abs]
  354. Strakowski, SM; Johnson, JL; Delbello, MP; Hamer, RM; Green, AI; Tohen, M; Lieberman, JA; Glick, I; Patel, JK; HGDH Research Group, (2005). Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.. Schizophrenia Research, 78(2-3), 161-169. [doi]  [abs]
  355. Marx, C; Naylor, J; Kilts, J; Allan, T; Smith, K; Szabo, S; Wagner, R; Buchanan, R; Keefe, R; Shampine, L (2017). RANDOMIZED CONTROLLED TRIAL OF A NEUROSTEROID INTERVENTION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 43, S14-S14.
  356. Jarskog, FF; Grove, RA; McEvoy, JP; Keefe, RSE; Lowy, MT; Horrigan, JP; Peykamian, MA (2012). Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy. Biological Psychiatry, 71(8), 63S-64S.
  357. Keefe, RSE; Meltzer, HA; Dgetluck, N; Gawryl, M; Koenig, G; Moebius, HJ; Lombardo, I; Hilt, DC (2015). Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.. Neuropsychopharmacology, 40(13), 3053-3060. [doi]  [abs]
  358. Ascher-Svanum, H; Nyhuis, AW; Stauffer, V; Kinon, BJ; Faries, DE; Phillips, GA; Schuh, K; Awad, AG; Keefe, R; Naber, D (2010). Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.. Curr Med Res Opin, 26(10), 2403-2410. [doi]  [abs]
  359. Bauer, IE; Ouyang, A; Mwangi, B; Sanches, M; Zunta-Soares, GB; Keefe, RSE; Huang, H; Soares, JC (2015). Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study.. J Psychiatr Res, 62, 115-122. [doi]  [abs]
  360. Keefe, RS; Silverman, JM; Siever, LJ; Cornblatt, BA (1991). Refining phenotype characterization in genetic linkage studies of schizophrenia.. Social Biology, 38(3-4), 197-218. [doi]  [abs]
  361. Lam, M; Collinson, SL; Eng, GK; Rapisarda, A; Kraus, M; Lee, J; Chong, SA; Keefe, RSE (2014). Refining the latent structure of neuropsychological performance in schizophrenia.. Psychol Med, 44(16), 3557-3570. [doi]  [abs]
  362. Hill, SK; Reilly, JL; Ragozzino, ME; Rubin, LH; Bishop, JR; Gur, RC; Gershon, ES; Tamminga, CA; Pearlson, GD; Keshavan, MS; Keefe, RSE; Sweeney, JA (2015). Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.. Schizophrenia Bulletin, 41(4), 940-950. [doi]  [abs]
  363. Mohamed, S; Rosenheck, R; Swartz, M; Stroup, S; Lieberman, JA; Keefe, RSE (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia.. American Journal of Psychiatry, 165(8), 978-987. [doi]  [abs]
  364. Graham, KA; Keefe, RS; Lieberman, JA; Calikoglu, AS; Lansing, KM; Perkins, DO (2015). Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.. Early Interv Psychiatry, 9(5), 397-405. [doi]  [abs]
  365. Lipkovich, IA; Deberdt, W; Csernansky, JG; Sabbe, B; Keefe, RS; Kollack-Walker, S (2009). Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.. Bmc Psychiatry, 9, 44. [doi]  [abs]
  366. Keefe, RSE; Davis, VG; Spagnola, NB; Hilt, D; Dgetluck, N; Ruse, S; Patterson, TD; Narasimhan, M; Harvey, PD (2015). Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.. Eur Neuropsychopharmacol, 25(2), 176-184. [doi]  [abs]
  367. Atkins, AS; Kraus, MS; Welch, M; Yuan, Z; Stevens, H; Welsh-Bohmer, KA; Keefe, RSE (2022). Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline.. Frontiers in Psychiatry, 13, 910896. [doi]  [abs]
  368. Keefe, RSE; Vinogradov, S; Medalia, A; Silverstein, SM; Bell, MD; Dickinson, D; Ventura, J; Marder, SR; Stroup, TS (2011). Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.. Schizophrenia Bulletin, 37(5), 1057-1065. [doi]  [abs]
  369. Keefe, RSE; Haig, GM; Marder, SR; Harvey, PD; Dunayevich, E; Medalia, A; Davidson, M; Lombardo, I; Bowie, CR; Buchanan, RW; Bugarski-Kirola, D; Carpenter, WT; Csernansky, JT; Dago, PL; Durand, DM; Frese, FJ; Goff, DC; Gold, JM; Hooker, CI; Kopelowicz, A; Loebel, A; McGurk, SR; Opler, LA; Pinkham, AE; Stern, RG (2016). Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.. Schizophrenia Bulletin, 42(1), 19-33. [doi]  [abs]
  370. Keefe, RSE; Green, MF; Harvey, PD (2020). Requisite Skills and the Meaningful Measurement of Cognition.. Jama Psychiatry, 77(11), 1103-1104. [doi]
  371. Artiola I Fortuny, L; Garolera, M; Hermosillo Romo, D; Feldman, E; Fernández Barillas, H; Keefe, R; Lemaître, MJ; Ortiz Martín, A; Mirsky, A; Monguió, I; Morote, G; Parchment, S; Parchment, LJ; Da Pena, E; Politis, DG; Sedó, MA; Taussik, I; Valdivia, F; De Valdivia, LE; Verger Maestre, K (2005). Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea.. Journal of Clinical and Experimental Neuropsychology, 27(5), 555-564. [doi]  [abs]
  372. Lui, S; Yao, L; Xiao, Y; Keedy, SK; Reilly, JL; Keefe, RS; Tamminga, CA; Keshavan, MS; Pearlson, GD; Gong, Q; Sweeney, JA (2015). Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives.. Psychol Med, 45(1), 97-108. [doi]  [abs]
  373. Kalali, A; Keefe, R; Pappadopulos, E; Vance, M (2015). Results of a Survey of Clinician Rated Outcome Measures in International Cns Clinical Trials. Neuropsychopharmacology, 40, S523-S524.
  374. Geffen, Y; Anand, R; Keefe, R; Davidson, M (2010). RESULTS OF PHASE 2B EAGLE TRIAL; A DOUBLE BLIND PLACEBO CONTROL STUDY EVALUATING THE EFFICACY AND SAFETY OF BL-1020, A GABA ENHANCED ANTIPSYCHOTIC FOR THE TREATMENT OF SCHIZOPHRENIA. Schizophrenia Research, 117(2-3), 212-212. [doi]
  375. Stroup, TS; Lieberman, JA; McEvoy, JP; Davis, SM; Swartz, MS; Keefe, RSE; Miller, AL; Rosenheck, RA; Hsiao, JK; CATIE Investigators, (2009). Results of phase 3 of the CATIE schizophrenia trial.. Schizophrenia Research, 107(1), 1-12. [19027269], [doi]  [abs]
  376. Kendler, KS; Keefe, RSE; Ohlsson, H; Sundquist, J; Sundquist, K (2023). Risk for psychiatric and substance use disorders as a function of transitions in Sweden's public educational system: a national study.. Psychol Med, 1-8. [doi]  [abs]
  377. Pandina, GJ; Bilder, R; Harvey, PD; Keefe, RSE; Aman, MG; Gharabawi, G (2007). Risperidone and cognitive function in children with disruptive behavior disorders.. Biological Psychiatry, 62(3), 226-234. [doi]  [abs]
  378. DAVIDSON, M; BERMAN, I; KEEFE, RS; DUVVI, K; PONTECORVO, M (1994). RISPERIDONE IN ELDERLY SCHIZOPHRENIC-PATIENTS. Schizophrenia Research, 11(2), 197-197.
  379. Podhorna, J; Hake, S; Groeschl, M; Pollentier, S; Atkins, A; Keefe, R (2019). S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL. Schizophrenia Bulletin, 45(Supplement_2), S315-S316. [doi]
  380. Kahn, RS; Keefe, RSE (2013). Schizophrenia is a cognitive illness: time for a change in focus.. Jama Psychiatry, 70(10), 1107-1112. [Gateway.cgi], [doi]  [abs]
  381. Krishnan, RR; Keefe, R; Kraus, M (2009). Schizophrenia is a disorder of higher order hierarchical processing.. Med Hypotheses, 72(6), 740-744. [doi]  [abs]
  382. Lieberman, JA; Drake, RE; Sederer, LI; Belger, A; Keefe, R; Perkins, D; Stroup, S (2008). Science and recovery in schizophrenia.. Psychiatric Services (Washington, D.C.), 59(5), 487-496. [18451003], [doi]  [abs]
  383. Rosenheck, R; Swartz, M; McEvoy, J; Stroup, TS; Davis, S; Keefe, RS; Hsiao, J; Lieberman, J (2007). Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.. Expert Rev Pharmacoecon Outcomes Res, 7(2), 103-111. [doi]  [abs]
  384. Keefe, RSE; Courtney, M; McEvoy, JM (1997). Self-monitoring deficits in schizophrenia: Autonoetic agnosia. Schizophrenia Research, 24(1-2), 110-110. [doi]
  385. Salgado, JV; Carvalhaes, CFR; Pires, ADM; Neves, MDCLD; Cruz, BF; Cardoso, CS; Lauar, H; Teixeira, AL; Keefe, RSE (2007). Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS).. Dementia & Neuropsychologia, 1(3), 260-265. [doi]  [abs]
  386. Conway, CR; Bollini, AM; Graham, BG; Keefe, RSE; Schiffman, SS; McEvoy, JP (2002). Sensory acuity and reasoning in delusional disorder.. Comprehensive Psychiatry, 43(3), 175-178. [11994833], [doi]  [abs]
  387. Davidson, M; Harvey, PD; Powchik, P; Parrella, M; White, L; Knobler, HY; Losonczy, MF; Keefe, RS; Katz, S; Frecska, E (1995). Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.. The American Journal of Psychiatry, 152(2), 197-207. [doi]  [abs]
  388. Keefe, RSE (2008). Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa), 7(1), 22-28. [doi]  [abs]
  389. Barbato, M; Liu, L; Penn, DL; Keefe, RSE; Perkins, DO; Woods, SW; Addington, J (2013). Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.. Schizophrenia Research, 150(2-3), 542-546. [doi]  [abs]
  390. Lim, K; Rapisarda, A; Keefe, RSE; Lee, J (2022). Social skills, negative symptoms and real-world functioning in individuals at ultra-high risk of psychosis.. Asian J Psychiatr, 69, 102996. [doi]  [abs]
  391. Keefe, RS; Arnold, MC; Bayen, UJ; Harvey, PD (1999). Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis.. Psychological Medicine, 29(4), 903-914. [doi]  [abs]
  392. Keefe, RSE; Poe, MP; McEvoy, JP; Vaughan, A (2003). Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.. Psychopharmacology, 169(3-4), 383-389. [12759802], [doi]  [abs]
  393. Keefe, RSE; Arnold, MC; Bayen, UJ; McEvoy, JP; Wilson, WH (2002). Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.. Schizophrenia Research, 57(1), 51-67. [12165376], [doi]  [abs]
  394. Segarra, N; Bernardo, M; Gutierrez, F; Justicia, A; Fernadez-Egea, E; Allas, M; Safont, G; Contreras, F; Gascon, J; Soler-Insa, PA; Menchon, JM; Junque, C; Keefe, RSE (2011). Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls.. Eur Psychiatry, 26(2), 69-73. [doi]  [abs]
  395. Kahn, PV; Walker, TM; Williams, TS; Cornblatt, BA; Mohs, RC; Keefe, RSE (2012). Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.. Schizophrenia Research, 142(1-3), 153-158. [doi]  [abs]
  396. Reichenberg, A; Caspi, A; Harrington, H; Houts, R; Keefe, RS; Murray, RM; Poulton, R; Moffitt, TE (2010). Static and Dynamic Cognitive Deficits in Childhood Precede Adult Schizophrenia: A 30-Year Study. Biological Psychiatry, 67(9), 12S-12S.
  397. Reichenberg, A; Caspi, A; Harrington, H; Houts, R; Keefe, R; Murray, R; Poulton, R; Moffitt, T (2010). STATIC AND DYNAMIC COGNITIVE DEFICITS IN CHILDHOOD PRECEDE ADULT SCHIZOPHRENIA: A 30-YEAR STUDY. Schizophrenia Research, 117(2-3), 175-175. [doi]
  398. Reichenberg, A; Caspi, A; Harrington, H; Houts, R; Keefe, RSE; Murray, RM; Poulton, R; Moffitt, TE (2010). Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.. American Journal of Psychiatry, 167(2), 160-169. [20048021], [doi]  [abs]
  399. Harvey, PD; Keefe, RS (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.. The American Journal of Psychiatry, 158(2), 176-184. [doi]  [abs]
  400. Kerfoot, KE; Rosenheck, RA; Petrakis, IL; Swartz, MS; Keefe, RSE; McEvoy, JP; Stroup, TS; CATIE Investigators, (2011). Substance use and schizophrenia: adverse correlates in the CATIE study sample.. Schizophrenia Research, 132(2-3), 177-182. [doi]  [abs]
  401. Keefe, RSE; Bollini, AM; Courtney, MC; Wilson, WH; McEvoy, JP (1999). Successful treatment of self-monitoring deficits predicts psychotic symptom decrease. Schizophrenia Research, 36(1-3), 172-172.
  402. Sand, M; Nakagome, K; Cordes, J; Brenner, R; Gründer, G; Keefe, R; Riesenberg, R; Walling, D; Daniels, K; Wang, L; Carter, K; Brown, D (2018). T205. Effect of BI 409306 on Positive and Negative Syndrome Scale in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Biological Psychiatry, 83(9), S207-S208. [doi]
  403. Seccomandi, B; Agbedjro, D; Bell, M; Keefe, R; Keshavan, M; Galderisi, S; Medalia, A; Fiszdon, J; Maj, M; Mucci, A; Cavallato, R; Wykes, T; Cella, M (2018). T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?. Schizophrenia Bulletin, 44(suppl_1), S196-S197. [doi]
  404. Kraus, M; Walker, T; Perkins, D; Keefe, R (2019). T32. INTACT AUDITORY PERCEPTION IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 45(Supplement_2), S215-S215. [doi]
  405. Ventura, J; Welikson, T; Subotnik, KL; Ered, A; Keefe, R; Hellemann, GH; Nuechterlein, KH (2018). T59. VIRTUAL REALTY ASSESSMENT OF FUNCTIONAL CAPACITY IN EARLY SCHIZOPHRENIA: ASSOCIATIONS WITH NEUROCOGNITION, FUNCTIONAL CAPACITY PERFORMANCE, AND DAILY FUNCTIONING. Schizophrenia Bulletin, 44(suppl_1), S136-S137. [doi]
  406. Keefe, RSE; Pani, L (2018). Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency).. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging, 3(11), 900-902. [doi]
  407. KEEFE, RSE; BLUM, C; MERHIGE, DM; LEES, SE; ZOLOT, DM; DAVIDSON, M; HARVEY, PD; DAVIS, KL (1993). TASKS FROM MONKEY CORTEX STUDIES AND SPECIFIC PREFRONTAL DYSFUNCTION IN SCHIZOPHRENIA. Biological Psychiatry, 33(6A), A92-A92.
  408. Harvey, PD; Keefe, RS (2012). Technology, society, and mental illness: Challenges and opportunities for assessment and treatment. Innovations in Clinical Neuroscience, 9(11-12), 47-50.  [abs]
  409. Keefe, R; Siu, C; Fox, K; Lowe, DA; Garibaldi, G; Santarelli, L; Murray, S (2009). TEST-RETEST CHARACTERISTICS OF THE MATRICS CONSENSUS COGNITIVE BATTERY IN A 20-SITE SCHIZOPHRENIA CLINICAL TRIAL OF R3487/MEM3454 VERSUS PLACEBO. Schizophrenia Bulletin, 35, 358-359.
  410. Bollini, AM; Arnold, MC; Keefe, RS (2000). Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls.. Schizophrenia Research, 45(1-2), 169-173. [doi]  [abs]
  411. Siever, LJ; Kalus, OF; Keefe, RS (1993). The boundaries of schizophrenia.. The Psychiatric Clinics of North America, 16(2), 217-244. [doi]  [abs]
  412. Keefe, RSE; Fox, KH; Davis, VG; Kennel, C; Walker, TM; Burdick, KE; Harvey, PD (2014). The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls.. J Affect Disord, 166, 86-92. [doi]  [abs]
  413. Keefe, RSE; Goldberg, TE; Harvey, PD; Gold, JM; Poe, M; Coughenour, L (2004). The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 67(1), 263-263.
  414. Keefe, RSE; Goldberg, TE; Harvey, PD; Gold, JM; Poe, MP; Coughenour, L (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.. Schizophrenia Research, 68(2-3), 283-297. [doi]  [abs]
  415. Bauer, IE; Keefe, R; Suchting, R; Green, C; Zunta-Soares, GB; Soares, JC (2014). The Brief Cognitive Assessment Test for Affective Disorders (BAC-A): A New Instrument for Assessing Cognitive Functioning in Bipolar Disorder. Biological Psychiatry, 75(9), 198S-198S.
  416. Kraus, MS; Gold, JM; Barch, DM; Walker, TM; Chun, CA; Buchanan, RW; Csernansky, JG; Goff, DC; Green, MF; Jarskog, LF; Javitt, DC; Kimhy, D; Lieberman, JA; McEvoy, JP; Mesholam-Gately, RI; Seidman, LJ; Ball, MP; Kern, RS; McMahon, RP; Robinson, J; Marder, SR; Keefe, RSE (2020). The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures.. Schizophrenia Research. Cognition, 19, 100161. [doi]  [abs]
  417. Frecska, E; Losonczy, MF; Keefe, RSE; Silverman, JM; Davidson, M; Davis, KL (1993). The characteristics of poor outcome, 'Kraepelinian' schizophrenia. European Neuropsychopharmacology, 3(3), 400. [doi]
  418. Meyer, JM; Nasrallah, HA; McEvoy, JP; Goff, DC; Davis, SM; Chakos, M; Patel, JK; Keefe, RSE; Stroup, TS; Lieberman, JA (2005). The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.. Schizophrenia Research, 80(1), 9-18. [doi]  [abs]
  419. Ventura, J; Reise, SP; Keefe, RSE; Baade, LE; Gold, JM; Green, MF; Kern, RS; Mesholam-Gately, R; Nuechterlein, KH; Seidman, LJ; Bilder, RM (2010). The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.. Schizophrenia Research, 121(1-3), 24-31. [doi]  [abs]
  420. Ventura, J; Reise, SP; Keefe, RSE; Hurford, IM; Wood, RC; Bilder, RM (2013). The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.. Schizophrenia Bulletin, 39(3), 583-591. [doi]  [abs]
  421. Rapisarda, A; Kraus, M; Tan, YW; Lam, M; Eng, GK; Lee, J; Subramaniam, M; Collinson, SL; Chong, SA; Keefe, RSE (2014). The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.. Schizophrenia Research, 156(2-3), 233-240. [doi]  [abs]
  422. Keefe, RS (1995). The contribution of neuropsychology to psychiatry.. The American Journal of Psychiatry, 152(1), 6-15. [doi]  [abs]
  423. Barbato, M; Colijn, MA; Keefe, RSE; Perkins, DO; Woods, SW; Hawkins, KA; Christensen, BK; Addington, J (2013). The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.. Psychiatry Research, 206(2-3), 195-199. [doi]  [abs]
  424. Penn, DL; Keefe, RSE; Davis, SM; Meyer, PS; Perkins, DO; Losardo, D; Lieberman, JA (2009). The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.. Schizophrenia Research, 115(1), 17-23. [doi]  [abs]
  425. Keefe, RS; Silva, SG; Perkins, DO; Lieberman, JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.. Schizophrenia Bulletin, 25(2), 201-222. [10416727], [doi]  [abs]
  426. Keefe, RSE; Hongbin, GU; Sweeney, JA; Perkins, DO; McEvoy, JP; Hamer, RM; Lieberman, JA (2006). The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison. Biological Psychiatry, 59(8), 231S-232S.
  427. Keefe, RSE; Gu, H; Perkins, D; Hamer, RM; Lieberman, JA (2006). The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison. Schizophrenia Research, 81, 54-54.
  428. EPSTEIN, JI; KEEFE, RSE; HARVEY, PD; MOHS, RC; ROITMAN, SEL; DAVIDSON, M; SIEVER, LJ (1994). THE EXTENT OF WORKING-MEMORY DEMANDS PREDICTS RESPONSE TO NEUROLEPTIC MEDICATION ON CONTINUOUS PERFORMANCE TESTS. Schizophrenia Research, 11(2), 153-154.
  429. Buchanan, RW; Keefe, RSE; Umbricht, D; Green, MF; Laughren, T; Marder, SR (2011). The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophrenia Bulletin, 37(6), 1209-1217. [doi]  [abs]
  430. Krystal, AD; Pizzagalli, DA; Mathew, SJ; Sanacora, G; Keefe, R; Song, A; Calabrese, J; Goddard, A; Goodman, W; Lisanby, SH; Smoski, M; Weiner, R; Iosifescu, D; Nurnberger, J; Szabo, S; Murrough, J; Shekhar, A; Potter, W (2018). The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.. Nat Rev Drug Discov, 18(1), 82-84. [doi]
  431. Keefe, RSE (2004). The functional hurdle: Connecting through cognition. Schizophrenia Research, 67(1), 277-277.
  432. Blokland, GAM; Del Re, EC; Mesholam-Gately, RI; Jovicich, J; Trampush, JW; Keshavan, MS; DeLisi, LE; Walters, JTR; Turner, JA; Malhotra, AK; Lencz, T; Shenton, ME; Voineskos, AN; Rujescu, D; Giegling, I; Kahn, RS; Roffman, JL; Holt, DJ; Ehrlich, S; Kikinis, Z; Dazzan, P; Murray, RM; Di Forti, M; Lee, J; Sim, K; Lam, M; Wolthusen, RPF; de Zwarte, SMC; Walton, E; Cosgrove, D; Kelly, S; Maleki, N; Osiecki, L; Picchioni, MM; Bramon, E; Russo, M; David, AS; Mondelli, V; Reinders, AATS; Falcone, MA; Hartmann, AM; Konte, B; Morris, DW; Gill, M; Corvin, AP; Cahn, W; Ho, NF; Liu, JJ; Keefe, RSE; Gollub, RL; Manoach, DS; Calhoun, VD; Schulz, SC; Sponheim, SR; Goff, DC; Buka, SL; Cherkerzian, S; Thermenos, HW; Kubicki, M; Nestor, PG; Dickie, EW; Vassos, E; Ciufolini, S; Reis Marques, T; Crossley, NA; Purcell, SM; Smoller, JW; van Haren, NEM; Toulopoulou, T; Donohoe, G; Goldstein, JM; Seidman, LJ; McCarley, RW; Petryshen, TL (2018). The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project.. Schizophrenia Research, 195, 306-317. [doi]  [abs]
  433. CORNBLATT, BA; KEEFE, RSE (1991). THE GENETICS OF MENTAL-ILLNESS - AN OVERVIEW. Social Biology, 38(3-4), R1-R5.
  434. Ang, MS; Abdul Rashid, NA; Lam, M; Rapisarda, A; Kraus, M; Keefe, RSE; Lee, J (2017). The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.. J Clin Psychopharmacol, 37(6), 651-656. [doi]  [abs]
  435. Kendler, KS; Ohlsson, H; Keefe, RSE; Sundquist, K; Sundquist, J (2018). The joint impact of cognitive performance in adolescence and familial cognitive aptitude on risk for major psychiatric disorders: a delineation of four potential pathways to illness.. Mol Psychiatry, 23(4), 1076-1083. [doi]  [abs]
  436. Keefe, RSE (2014). The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.. The Journal of Clinical Psychiatry, 75 Suppl 2, 8-13. [doi]  [abs]
  437. Lee, J; Rekhi, G; Mitter, N; Bong, YL; Kraus, MS; Lam, M; Rapisarda, A; Lee, T-S; Subramaniam, M; Chong, SA; Keefe, RSE (2013). The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.. Schizophrenia Research, 151(1-3), 279-283. [24139196], [doi]  [abs]
  438. Burdick, KE; Goldberg, TE; Cornblatt, BA; Keefe, RS; Gopin, CB; Derosse, P; Braga, RJ; Malhotra, AK (2011). The MATRICS consensus cognitive battery in patients with bipolar I disorder.. Neuropsychopharmacology, 36(8), 1587-1592. [doi]  [abs]
  439. Nuechterlein, KH; Green, MF; Kern, RS; Baade, LE; Barch, DM; Cohen, JD; Essock, S; Fenton, WS; Frese, FJ; Gold, JM; Goldberg, T; Heaton, RK; Keefe, RSE; Kraemer, H; Mesholam-Gately, R; Seidman, LJ; Stover, E; Weinberger, DR; Young, AS; Zalcman, S; Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.. The American Journal of Psychiatry, 165(2), 203-213. [doi]  [abs]
  440. Kern, RS; Nuechterlein, KH; Green, MF; Baade, LE; Fenton, WS; Gold, JM; Keefe, RSE; Mesholam-Gately, R; Mintz, J; Seidman, LJ; Stover, E; Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.. The American Journal of Psychiatry, 165(2), 214-220. [doi]  [abs]
  441. Kern, RS; Gold, JM; Dickinson, D; Green, MF; Nuechterlein, KH; Baade, LE; Keefe, RSE; Mesholam-Gately, RI; Seidman, LJ; Lee, C; Sugar, CA; Marder, SR (2011). The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.. Schizophrenia Research, 126(1-3), 124-131. [doi]  [abs]
  442. Crowley, JJ; Keefe, RSE; Perkins, DO; Stroup, TS; Lieberman, JA; Sullivan, PF (2008). The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.. Am J Med Genet B Neuropsychiatr Genet, 147B(7), 1298-1300. [doi]  [abs]
  443. Keefe, RSE; Cornblatt, BA (1996). The neuropsychology of schizophrenia - David,AS, Cutting,JC. Contemporary Psychology: a Journal of Reviews, 41(9), 900-902.
  444. Lim, J; Lee, S-A; Lam, M; Rapisarda, A; Kraus, M; Keefe, RSE; Lee, J (2016). The relationship between negative symptom subdomains and cognition.. Psychol Med, 46(10), 2169-2177. [doi]  [abs]
  445. Keefe, RSE; Lees Roitman, S; Dupre, RL; Harvey, PD; Davis, KL; Mohs, RC (1995). The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction. Schizophrenia Research, 15(1-2), 123-123. [doi]
  446. Marquez, E; Keefe, RSE; Purdon, SE; Rock, SL; Alaka, KJ; Ahmed, S; Mohs, RC (2004). The relationship of cognition changes and other symptoms following antipsychotic treatment. Biological Psychiatry, 55, 175S-175S.
  447. Keefe, RSE; Poe, M; Walker, TM; Harvey, PD (2006). The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.. Journal of Clinical and Experimental Neuropsychology, 28(2), 260-269. [doi]  [abs]
  448. Addington, J; Liu, L; Perkins, DO; Carrion, RE; Keefe, RSE; Woods, SW (2017). The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms.. Schizophrenia Bulletin, 43(1), 57-63. [doi]  [abs]
  449. Keefe, RSE; Poe, M; Walker, TM; Kang, JW; Harvey, PD (2006). The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.. The American Journal of Psychiatry, 163(3), 426-432. [doi]  [abs]
  450. Keefe, R; Atkins, A; Davis, V; Spagnola, N; Hilt, D; Dgetluck, N; Ruse, S; Patterson, T; Narasimhan, M; Harvey, PD (2015). THE SCHIZOPHRENIA COGNITION RATING SCALE: RELIABILITY, VALIDITY AND SENSITIVITY. Schizophrenia Bulletin, 41, S51-S52.
  451. Chia, MY; Chan, WY; Chua, KY; Lee, H; Lee, J; Lee, R; Lim, C; Tay, E; Woon, PS; Keefe, RSE; Sim, K (2010). The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.. Psychiatry Research, 178(1), 33-38. [doi]  [abs]
  452. Chong, S-A; Campbell, A; Chee, M; Liu, J; Marx, C; McGorry, P; Subramaniam, M; Yung, A; Keefe, RSE (2011). The Singapore flagship programme in translational and clinical research in psychosis.. Early Interv Psychiatry, 5(4), 290-300. [doi]  [abs]
  453. Rakesh, G; Mischel, NA; Luber, B; Keefe, RSE; Emory, S; Lisanby, SH; Szabo, ST (2020). Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study.. J Ect, 36(1), 72-74. [doi]
  454. Romero, HR; Monsch, AU; Hayden, KM; Plassman, BL; Atkins, AS; Keefe, RSE; Brewster, S; Chiang, C; O'Neil, J; Runyan, G; Atkinson, MJ; Crawford, S; Budur, K; Burns, DK; Welsh-Bohmer, KA (2018). TOMMORROW neuropsychological battery: German language validation and normative study.. Alzheimer'S & Dementia (New York, N. Y.), 4, 314-323. [doi]  [abs]
  455. Keefe, RSE (2016). Treating cognitive impairment in depression: an unmet need.. Lancet Psychiatry, 3(5), 392-393. [doi]
  456. Keefe, RSE (2004). Treatment of cognitive deficits in first episode schizophrenia. The International Journal of Neuropsychopharmacology, 7, S87-S87.
  457. Keefe, RS; Seidman, LJ; Christensen, BK; Yurgelun-Todd, DA; Lewine, RR; Sitskoorn, MM; Lieberman, JA (2001). Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis. Schizophrenia Research, 49(1-2), 234-234.
  458. Caroff, SN; Davis, VG; Miller, DD; Davis, SM; Rosenheck, RA; McEvoy, JP; Campbell, EC; Saltz, BL; Riggio, S; Chakos, MH; Swartz, MS; Keefe, RSE; Stroup, TS; Lieberman, JA; CATIE Investigators, (2011). Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.. The Journal of Clinical Psychiatry, 72(3), 295-303. [20816031], [doi]  [abs]
  459. Keefe, RSE; Harvey, PD (2015). Understanding symbol coding in schizophrenia.. Biol Psychiatry, 78(11), 744-746. [doi]
  460. Volovyk, SV; Keefe, RS (2010). UNIQUE OPPORTUNITY FOR COHERENT INSIGHTS INTO THE NATURE OF EARTH/SPACE NATURAL RADIATION EFFECTS ON MAN'S BRAIN DISORDERS. Schizophrenia Research, 117(2-3), 530-531. [doi]
  461. Hochberger, WC; Hill, SK; Nelson, CLM; Reilly, JL; Keefe, RSE; Pearlson, GD; Keshavan, MS; Tamminga, CA; Clementz, BA; Sweeney, JA (2016). Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives.. Schizophrenia Research, 170(1), 156-161. [doi]  [abs]
  462. Xavier, RM; Pan, W; Dungan, JR; Keefe, RSE; Vorderstrasse, A (2018). Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.. Schizophrenia Research, 193, 83-90. [doi]  [abs]
  463. Rashid, NAA; Lim, J; Lam, M; Chong, S-A; Keefe, RSE; Lee, J (2013). Unraveling the relationship between obesity, schizophrenia and cognition.. Schizophrenia Research, 151(1-3), 107-112. [doi]  [abs]
  464. Darrow, SM; Pizzagalli, DA; Smoski, M; Mathew, SJ; Nurnberger, J; Lisanby, SH; Iosifescu, D; Murrough, JW; Yang, H; Weiner, RD; Sanacora, G; Keefe, RSE; Song, A; Goodman, W; Whitton, AE; Potter, WZ; Krystal, AD (2023). Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study.. J Affect Disord, 339, 584-592. [doi]  [abs]
  465. Harvey, PD; Khan, A; Keefe, RSE (2017). Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience.. Innovations in Clinical Neuroscience, 14(11-12), 18-22.  [abs]
  466. Matza, LS; Phillips, GA; Revicki, DA; Ascher-Svanum, H; Malley, KG; Palsgrove, AC; Faries, DE; Stauffer, V; Kinon, BJ; George Awad, A; Keefe, RSE; Naber, D (2012). Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.. Psychiatry Research, 200(2-3), 835-842. [doi]  [abs]
  467. Keefe, R; Ruse, S; Davis, V; Atkins, A; Patterson, T; Narasimhan, M; Harvey, PD (2015). VALIDATION OF A COMPUTERIZED ASSESSMENT OF FUNCTIONAL CAPACITY. Schizophrenia Bulletin, 41, S177-S178.
  468. Keefe, R; Ruse, S; Davis, V; Atkins, A; Patterson, T; Narasimhan, M; Harvey, P (2014). Validation of A Computerized Assessment of Functional Capacity. Neuropsychopharmacology, 39, S475-S476.
  469. Keefe, RSE; Davis, VG; Atkins, AS; Vaughan, A; Patterson, T; Narasimhan, M; Harvey, PD (2016). Validation of a Computerized test of Functional Capacity.. Schizophrenia Research, 175(1-3), 90-96. [doi]  [abs]
  470. Matza, LS; Phillips, GA; Revicki, DA; Ascher-Svanum, H; Malley, KG; Palsgrove, AC; Faries, DE; Stauffer, V; Kinon, BJ; Awad, AG; Keefe, RS; Naber, D (2012). Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.. Patient Preference and Adherence, 6, 521-532. [Gateway.cgi], [doi]  [abs]
  471. Cecchi, M; Adachi, M; Basile, A; Buhl, DL; Chadchankar, H; Christensen, S; Christian, E; Doherty, J; Fadem, KC; Farley, B; Forman, MS; Honda, S; Johannesen, J; Kinon, BJ; Klamer, D; Marino, MJ; Missling, C; O'Donnell, P; Piser, T; Puryear, CB; Quirk, MC; Rotte, M; Sanchez, C; Smith, DG; Uslaner, JM; Javitt, DC; Keefe, RSE; Mathalon, D; Potter, WZ; Walling, DP; Ereshefsky, L (2023). Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.. Schizophrenia Research, 254, 178-189. [doi]  [abs]
  472. Bralet, M-C; Falissard, B; Neveu, X; Lucas-Ross, M; Eskenazi, A-M; Keefe, RSE (2007). Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.. European Psychiatry, 22(6), 365-370. [doi]  [abs]
  473. Sachs, G; Winklbaur, B; Jagsch, R; Keefe, RSE (2011). Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results.. Eur Psychiatry, 26(2), 74-77. [doi]  [abs]
  474. Mazhari, S; Parvaresh, N; Eslami Shahrbabaki, M; Sadeghi, MM; Nakhaee, N; Keefe, RSE (2014). Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.. Psychiatry and Clinical Neurosciences, 68(2), 160-166. [doi]  [abs]
  475. Mazhari, S; Ghafaree-Nejad, AR; Soleymani-Zade, S; Keefe, RSE (2017). Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia.. Asian J Psychiatr, 27, 12-15. [doi]  [abs]
  476. Atkins, AS; Tseng, T; Vaughan, A; Twamley, EW; Harvey, P; Patterson, T; Narasimhan, M; Keefe, RSE (2017). Validation of the tablet-administered Brief Assessment of Cognition (BAC App).. Schizophrenia Research, 181, 100-106. [doi]  [abs]
  477. Araújo, GE; Resende, CBD; Cardoso, ACA; Teixeira, AL; Keefe, RSE; Salgado, JV (2015). Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).. Clinics (Sao Paulo, Brazil), 70(4), 278-282. [doi]  [abs]
  478. Davis, KL; Buchsbaum, MS; Shihabuddin, L; Spiegel-Cohen, J; Metzger, M; Frecska, E; Keefe, RS; Powchik, P (1998). Ventricular enlargement in poor-outcome schizophrenia.. Biological Psychiatry, 43(11), 783-793. [doi]  [abs]
  479. Kilciksiz, CM; Keefe, R; Benoit, J; Öngür, D; Torous, J (2020). Verbal memory measurement towards digital perspectives in first-episode psychosis: A review.. Schizophrenia Research. Cognition, 21, 100177. [doi]  [abs]
  480. Harvey, PD; Khan, A; Atkins, A; Keefe, RS (2019). Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes.. Psychiatry Research, 277, 58-63. [doi]  [abs]
  481. Ventura, J; Welikson, T; Ered, A; Subotnik, KL; Keefe, RSE; Hellemann, GS; Nuechterlein, KH (2020). Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.. Early Interv Psychiatry, 14(1), 106-114. [doi]  [abs]
  482. Ruse, SA; Harvey, PD; Davis, VG; Atkins, AS; Fox, KH; Keefe, RSE (2014). Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.. Schizophrenia Research. Cognition, 1(1), e21-e26. [doi]  [abs]
  483. Turner, TH; Atkins, A; Keefe, RSE (2021). Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease.. J Parkinsons Dis, 11(4), 1917-1925. [doi]  [abs]
  484. Roitman, SEL; Keefe, RSE; Mitropoulou, V; Dupre, RL; Siever, LJ (1997). Visuospatial working memory in schizotypal personality disorder. Biological Psychiatry, 41, 355-355.
  485. Roitman, SEL; Keefe, RSE; Dupre, RL; Siever, LJ (1996). Visuospatial working memory in schizotypal personality disorder. Biological Psychiatry, 39(7), 266-266.
  486. Roitman, SE; Mitropoulou, V; Keefe, RS; Silverman, JM; Serby, M; Harvey, PD; Reynolds, DA; Mohs, RC; Siever, LJ (2000). Visuospatial working memory in schizotypal personality disorder patients.. Schizophrenia Research, 41(3), 447-455. [doi]  [abs]
  487. Swartz, MS; Stroup, TS; McEvoy, JP; Davis, SM; Rosenheck, RA; Keefe, RSE; Hsiao, JK; Lieberman, JA (2008). What CATIE found: results from the schizophrenia trial.. Psychiatric Services (Washington, D.C.), 59(5), 500-506. [18451005], [doi]  [abs]
  488. Fava, M; Mahableshwarkar, AR; Jacobson, W; Zhong, W; Keefe, RS; Olsen, CK; Jaeger, J (2018). What is the overlap between subjective and objective cognitive impairments in MDD?. Ann Clin Psychiatry, 30(3), 176-184.  [abs]
  489. Keefe, RSE (2021). Where do we cut the bell-shaped curve of CIAS?. Schizophrenia Research, 228, 633-634. [doi]
  490. Sim, K; Yang, GL; Loh, D; Poon, LY; Sitoh, YY; Verma, S; Keefe, R; Collinson, S; Chong, SA; Heckers, S; Nowinski, W; Pantelis, C (2009). White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study.. Psychiatry Research, 172(2), 121-127. [doi]  [abs]
  491. Keefe, RSE (2019). Why are there no approved treatments for cognitive impairment in schizophrenia?. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa), 18(2), 167-168. [doi]
  492. Keefe, RSE; Blum, C; Roitman, SL; Harvey, PD; Davidson, M; Mohs, RC; Davis, KL (1994). Working memory dysfunction in Kraepelinian schizophrenics. Biological Psychiatry, 35(9), 660-660. [doi]
  493. Kristian Hill, S; Buchholz, A; Amsbaugh, H; Reilly, JL; Rubin, LH; Gold, JM; Keefe, RSE; Pearlson, GD; Keshavan, MS; Tamminga, CA; Sweeney, JA (2015). Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment.. Schizophrenia Research, 166(1-3), 310-315. [doi]  [abs]
  494. KEEFE, RSE; BLUM, C; HARVEY, PD; DAVIDSON, M; ROITMAN, SE; DAVIS, KL (1994). WORKING-MEMORY DEFICITS IN SCHIZOPHRENICS WITH SEVERE SELF-CARE DYSFUNCTION. Schizophrenia Research, 11(2), 158-158.
  495. Keefe, RSE (2002). [The evaluation of cognitive dysfunctions in schizophrenia].. L'Encephale, 28 Spec No 2 Pt 2(5 II), S11-S13.

Papers Published

  1. Davidson, M., and Keefe, R.S.E. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research 1995; 17:123-129..
  2. Davidson, M., Harvey, P.D., Powchik, P., Parrella, M., White, L., Knobler, H.Y., Losonczy, M.F., Keefe, R.S.E., Katz, S., and Frecska, E. Severity of symptoms in geriatric schizophrenic patients. American Journal of Psychiatry 1995; 152:197-207..
  3. Davis, K.L., Buchsbaum, M.S., Shihabuddin, L., Spiegel-Cohen, J., Metzger, M., Frecska, E., Keefe, R.S., and Powchik, P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry 1998;43:783-793..
  4. Epstein, J.I., Keefe, R.S.E., Lees Roitman, S.E., Harvey, P.D., and Mohs, R.C. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry 1996;39:902-905..
  5. Harvey, P.D., and Keefe, R.S.E. Cognition and the new antipsychotics. Journal of Advances in Schizophrenia and Brain Research 1998;1:2-8..
  6. Harvey, P.D., and Keefe, R.S.E. Studies of cognitive change with treatment in schizophrenia. American Journal of Psychiatry, 2001; 158: 176-184..
  7. Harvey, P.D., Davidson, M., White, L., Keefe, R.S.E., Hirschowitz, J., Mohs, R.C., and Davis, K.L. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the BPRS. Biological Psychiatry 1996;40:755-761..
  8. Harvey, P.D., Keefe, R.S.E., Mitropolou, V., DuPre, R.L., Lees Roitman, S.E., Mohs, R.C., and Siever, L.J. Information processing and vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research 1996;60:49-56..
  9. Kahn, R.S., Harvey P.D., Davidson, M., Keefe, R.S.E., Apter, S., Neale, J.M., Mohs, R.C., and Davis, K.L. Neuropsychological functioning correlates of central monoamine function in chronic schizophrenia. Schizophrenia Research. 1994; 11:217-224..
  10. Keefe R.S.E., and Cornblatt, B.A. Neuropsychology of Schizophrenia, edited by A.S. David and J.C. Cutting. Contemporary Psychology (in press)..
  11. Keefe R.S.E., and Cornblatt, B.A. Neuropsychology of Schizophrenia, edited by A.S. David and J.C. Cutting. Contemporary Psychology (in press)..
  12. Keefe, R. Progress in Experimental Personality and Psychopathology Research, vol. 15, edited by E.F. Walker, R.H. Dworkin, and B.A. Cornblatt. American Journal of Psychiatry 1995;152:288-289..
  13. Keefe, R.S.E. Neurocognition. 2001: pp. 192-205, In Current Issues in the Psychopharmacology of Schizophrenia, Breier, A., et al, eds. Lippincott, Williams & Wilkins: Philadelphia..
  14. Keefe, R.S.E. Neuropsychological assessment of patients with schizophrenia. Clinical Advances in the Treatment of Psychiatric Disorders 1996; 10(5):16, 11-13..
  15. Keefe, R.S.E. The contribution of neuropsychology to psychiatry. American Journal of Psychiatry 1995; 152:6-15..
  16. Keefe, R.S.E. and Harvey, P.D. Schizophrenia. In: McGraw Hill Encyclopedia of Science & Technology, 9th edition (2001)..
  17. Keefe, R.S.E. The neurobiology of disturbances of the self: Autonoetic agnosia in schizophrenia. 1998: pp. 142-173. In: Insight and Psychosis, X.F. Amador and A. David, eds., New York: Oxford University Press..
  18. Keefe, R.S.E., and Harvey P.D. (1994) Understanding Schizophrenia: A Guide to the New Research on Causes and Treatment, New York: The Free Press (Division of Simon and Schuster), 283 pp..
  19. Keefe, R.S.E., Frecska, E., Apter, S., Davidson, M., Hirschowitz, J., and Davis, K.L. Clinical characteristics of kraepelinian schizophrenia: Replication and extension of previous findings. American Journal of Psychiatry 1996; 153: 806-811..
  20. Keefe, R.S.E., Lees Roitman, S.E., Harvey, P.D. Blum, C., DuPre, R.L., Davidson, M., and Davis, K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research, 1995; 17:25-33..
  21. Keefe, R.S.E., Mohs, R.C., Losonczy, M.F., Davidson, M., Silverman, J.M., Kendler, K.S., Nora, R., Horvath, T.B., and Davis, K.L. Characteristics of very poor outcome schizophrenia. American Journal of Psychiatry 1987; 144:889-895..
  22. Keefe, R.S.E., Practical applications of neuropsychology in clinical psychiatry. Directions in Psychiatry 1996; 16(4):1-8..
  23. Keefe, R.S.E., Silverman, J., Mohs, R.C., Siever, L.J, Harvey, P.D., Friedman, L., Lees Roitman S.E., DuPre R.L., Smith C.J., Schmeidler, J., and Davis, K.L. Eye tracking, attention, and schizotypal personality symptoms in nonpsychotic relatives of schizophrenic patients. Archives of General Psychiatry 54: 169-177, 1997..
  24. Keefe, R.S.E., Silverman, J.M., Lees Roitman, S.E., Harvey, P.D., Duncan, A., Alroy, D., Siever, L.J, Mohs, R.C., and Davis, K.L. Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research 1994; 53:1-12..
  25. McEvoy, J.P., and Keefe, R.S.E. Informing subjects of risks and benefits. 1999: pp. 129-157. In: Ethics in Psychiatric Research, H.A. Pincus, J.A. Lieberman, and S. Ferris, eds., Washington, DC: American Psychiatric Association.
  26. Siever, L.J., Bergman, A.J., and Keefe, R.S.E. The schizophrenia spectrum personality disorders. In: Schizophrenia, S.R. Hirsch and D.R. Weinberger, eds., pp. 87-105, Oxford: Blackwell University Press, 1995..
  27. Siever, L.J., Freidman, L., Moskowitz, J., Mitropoulou, V., Keefe, R.S.E., Lees Roitman, S, Merhige, D., Trestman, R., Silverman, J.M., and Mohs, R.C. Eye movement impairment and schizotypal psychopathology. American Journal of Psychiatry 1994; 151:1209-1216..
  28. Trestman, R.L., Keefe, R.S.E., Mitropoulou, V., Harvey, P.D. deVegvar M.L., Lees Roitman, S.E., Davidson, M., Aaronson, A., Silverman, J.M., and Siever, L.J. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research 1995; 59:127-136..
  29. Vocisano, C., Klein, D.N., Keefe, R.S.E., Dienst, E.R., Kincaid, M.M. Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder. American Journal of Psychiatry 1996:153:248-255..
  30. Wainberg, M.L. Keefe, R.S.E., Siever L.J. The neuropsychiatry of schizotypal personality disorder. In: Neuropsychiatry of Behavior Disorders, J.J. Ratey, ed., pp. 210-229, Oxford: Blackwell University Press, 1995..
  31. Yehuda R., Keefe, R.S.E., Harvey, P.D., Levengood, R.A., Gerber D.K., Geni J., and Siever, L.J. Learning and memory deficits in combat veterans with post-traumatic stress disorder. American Journal of Psychiatry 1995; 152:137-139..

Chapters in Books

  1. Vance, M; Pappadopulos, E; Keefe, R; Kalali, A "Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia." Beyond Assessment of Quality of Life in Schizophrenia. Springer International Publishing, January, 2016: 53-62. [doi]  [abs]
  2. Harvey, PD; Keefe, RSE "The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date." ESSENTIAL CNS DRUG DEVELOPMENT. 2012: 177-191.
Duke University * Arts & Sciences * Faculty * Staff * Grad * Postdocs * Reload * Login